Small molecule IL-17A modulators

By developing a fused bicyclic compound, the problems of high cost and non-oral applications of existing IL-17A inhibitors have been solved, and the effective regulation and treatment convenience of IL-17A is achieved, and it is suitable for autoimmune and inflammatory diseases. treatment.

CN119053589APending Publication Date: 2024-11-29BEIGENE (SUZHOU) CO., LTD.

Patent Information

Application Number
CN202380035008.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-21
Filing Date
2023-04-20
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing IL-17A inhibitors are mainly monoclonal antibodies, which have high cost, non-oral application and poor tissue penetration, and it is difficult to quickly withdraw related adverse events. It is necessary to develop oral small molecule IL with different structures- 17A regulator.

Method used

A fused bicyclic compound has been developed to treat autoimmune and inflammatory diseases by inhibiting IL-17A activity, with oral feasibility and flexible treatment options.

Benefits of technology

Effective regulation of IL-17A is achieved, providing an oral treatment plan, improving the convenience and safety of treatment, and reducing the risk of related adverse events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005091426680000031
    Figure BDA0005091426680000031
  • Figure BDA0005091426680000101
    Figure BDA0005091426680000101
  • Figure BDA0005091426680000111
    Figure BDA0005091426680000111
Patent Text Reader

Abstract

Disclosed herein are fused bicyclic compounds useful as modulators of small molecule IL-17A. Disclosed herein are the use of these small molecule IL-17A modulators for lowering IL-17 activity by inhibition, and the use of such compounds for the treatment of autoimmune or inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Disclosed herein are fused bicyclic compounds useful as small molecule IL-17A modulators. Disclosed herein are the use of these small molecule IL-17A modulators for reducing IL-17 activity by inhibition, and the use of such compounds for treating autoimmune or inflammatory diseases. Background Art

[0002] The interleukin-17 (IL-17) family is a group of proinflammatory cytokines that participate in the immune response of tissues and play a key role in chronic inflammation. The secretion of IL-17 can stimulate the production of other proinflammatory cytokines (IL-1, IL-6, G-CSF, GM-CSF and TNF) and chemokines (CXCL1, CXCL2, CXCL5, CCL2, CCL7, CCL20 and IL-8), matrix metalloproteinases (MMP1, MMP3, MMP9 and MMP13) and antimicrobial peptides (β-defensins, S-100 proteins) (Frontiers in Immunology (2020) 11: 947). The IL-17 family consists of 7 members, including IL17A to IL17F and vIL-17A. IL-17A, as the most widely studied founder member, is associated with host defense against various microbial pathogens and tissue inflammation (Gene (2017) 614: 8-14). IL-17A consists of 155 amino acids, and the molecular weight of the homodimer is 30-35 kDa (European Respiratory Journal (2005): 159-172). IL-17F (a close relative of IL-17A) shares about 50% amino acid sequence homology with IL-17A at its 163 amino acids, and is often co-expressed with IL-17A (Immunity (2004): 467-476). Both IL-17A and IL-17F are secreted from T helper cells (Th17) and expressed as homodimers or IL-17A / F heterodimers (European Respiratory Journal (2005): 159-172). The IL-17 receptor family consists of five members: IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE. All five receptors share a common cytoplasmic motif named SEFIR domain (Frontiers in Immunology 11 (2020): 947). IL-17A and IL-17F signal through the same receptor complex IL-17R, which consists of two subunits: IL-17RA and IL-17RG (Gene (2017) 614: 8-14). The corresponding receptors activate downstream pathways of these signaling, including NFκB, MAPK and C / EBP, to induce the expression of antimicrobial peptides, cytokines and chemokines (Frontiers in Immunology (2020): 947). IL-17A promotes tissue inflammation and bone remodeling. It can act on various cell types: keratinocytes, endothelial cells, fibroblasts, osteoclasts, chondrocytes and osteoblasts (Archives of oral biology (2014): 897-905).

[0003] Abnormal autoimmune responses that increase secreted IL-17A are observed in many autoimmune diseases including psoriasis, spondyloarthritis, rheumatoid arthritis, and multiple sclerosis (Gene (2017) 614: 8-14). One potential treatment for these diseases is the development of IL-17A inhibitors. Currently, the FDA has approved several monoclonal antibodies targeting IL-17A for the treatment of moderate to severe plaque psoriasis (Expert Opin. Biol. Ther. (2019), 19, 45-54): secukinumab (Cosentyx, Novartis), ixekizumab (Taltz, Eli Lilly) and brodalumab (Kyntheum, LEO Pharma / AstraZeneca). Bimekizumab (UCB) is a bispecific anti-IL-17A / IL-17F humanized monoclonal antibody approved by the EC in 2021. However, since monoclonal antibodies have many disadvantages, such as high product cost, non-oral application, poor tissue penetration and generally long half-life (Chem. Biol. (2014) 21, 1102-1114), small molecules that will exhibit the same biological results are still being sought. Some disclosures describing small molecules having IL-17A inhibitory activity are known (WO2014066726, WO2018229079, WO2019138017, WO2019223718, WO2020182666, WO2020011731, WO2020127685, WO2020163554, WO2021055376, WO2021098844, 2020163554WO2020146194, WO2021204801, WO2021170627, WO2021098844, WO2021222404, WO2021220183). Several small molecule inhibitors targeting the protein / protein interaction of IL-17A and IL-17RA have now advanced into clinical trials. Oral administration and flexible treatment regimens should be major aspects in favor of patient convenience. The possibility of rapid withdrawal of small molecule drugs when target-related adverse events occur may render the approved safety profile. Therefore, there is a continuing need to develop small molecule IL-17A modulators with different structures, especially orally administrable. Summary of the invention

[0004] In one embodiment, disclosed herein is a fused bicyclic compound of formula (I). This embodiment includes the following aspects:

[0005] Aspect 1. A compound of formula (I):

[0006]

[0007] or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a deuterated analog thereof, wherein:

[0008] Cy1 is a 5-6 membered aromatic ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 3 replace;

[0009] n3 is independently 0, 1, 2 or 3;

[0010] Cy2 is a 4-8 membered saturated or partially or fully unsaturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is substituted by at least one substituent R 1 and / or R 2 replace;

[0011] n1 is 0 or 1;

[0012] n2 is 0, 1, or 2;

[0013] n1 and n2 are not 0 at the same time;

[0014] Cy1 and Cy2 are fused to each other;

[0015] Cy3 is a 3-12 membered saturated or partially or fully unsaturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is optionally substituted by at least one substituent R 6 replace;

[0016] n6 is independently 0, 1, 2, 3, 4 or 5, provided that the valence theory is satisfied;

[0017] X 1 Is a single bond or -CR 9 R 10 -;

[0018] R 1 Independently selected from H or

[0019] Where X 2 is N or C(R 15 );

[0020] X 3 is -C(O)-, -S(O)- or -S(O) 2 -;

[0021] n11 and n12 are each independently 1, 2 or 3;

[0022] n14 is 0 or 1;

[0023] R 15 Selected from hydrogen, halogen, -C 1-8 Alkyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, -CN, -OR 15a 、-NR 15a R 15b or -NR 15a COR 15b ;-C 1-8 Alkyl, C 3 -C 8 Each of the cycloalkyl group and the 3- to 8-membered heterocyclic group is optionally substituted by at least one substituent R 15c replace;

[0024] R 15a and R 15b are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 15d replace;

[0025] R 15c and R 15d is independently halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3 -C 8 Cycloalkyl, -C 3 -C 8 Halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0026] R 11a , R 11b , R 12a and R 12b are each independently selected from hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -OR 11c 、-COR 11c , -CO 2 R 11c 、-CONR 11c R 11d 、-NR 11c R 11d or -NR 11c COR 11d ;-C 1-8 Alkyl, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 11e Replace, or

[0027] (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R 12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the atoms to which they are attached form a 3- to 8-membered unsaturated or saturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 11f replace;

[0028] R 11e and R11f is independently hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR 11g , thio (=S), -SR 11g 、-CN、-SO 2 R 11g 、-SO 2 NR 11g R 11h 、-COR 11g , -CO 2 R 11h 、-CONR 11g R 11h 、-NR 11g R 11h 、-NR 11g COR 11h 、-NR 11g CO 2 R 11h or -NR 11g SO 2 R 11h ;-C 1-8 Alkyl, -C 1-8 Alkoxy, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 11i replace;

[0029] R 11c , R 11d , R 11g and R 11h are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 11j replace;

[0030] R 11i and R 11j is independently halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, -C 3 -C 8 Halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituted group, halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, -C 3 -C 8 Halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl substitution;

[0031] R 13 , R 14a and R 14b are each independently selected from hydrogen, -C 1-8Alkyl, -C 3 -C 8 Cycloalkyl or 3- to 8-membered heterocyclic group; -C 1-8 Alkyl, -C 3 -C 8 Each of the cycloalkyl group and the 3- to 8-membered heterocyclic group is optionally substituted by at least one substituent R 13a replace;

[0032] R 13a is independently at each occurrence halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, -C 3 -C 8 Halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0033] R 2 Independently selected from H, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -COR 2a , -CO 2 R 2a 、-CONR 2a R 2b 、-NR 2a R 2b or -NR 2a COR 2b , -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 2c replace; or

[0034] When two adjacent or 2When taken together with the carbon atoms to which they are attached to form a 3- to 8-membered unsaturated or saturated ring, the ring contains 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2c replace;

[0035] R 2a and R 2b are each independently selected from hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 2d replace; or

[0036] R 2a and R 2b Together with the nitrogen atom to which they are attached, they form a 3- to 8-membered unsaturated or saturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2d replace;

[0037] R 2c and R 2d is independently hydrogen, halogen, -C 1-8 Alkyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR 2e 、-SR 2e 、-CN、-COR 2e , -CO 2 R 2e 、-CONR 2e R 2f 、-NR 2e R 2f 、-NR 2e COR 2f or -NR 2e CO 2 R2f ;-C 1-8 Alkyl, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 2g replace;

[0038] R 2e and R 2f are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 2h replace;

[0039] R 2g and R 2h is independently halogen, -OH, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, -C 3 -C 8 Halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0040] When n1 and n2 are both 1, R1 and R 2 are concomitant or adjacent;

[0041] R 3 are independently selected from hydrogen, halogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, -C 3 -C 8 Cycloalkyl or -CN, where -C 1-8 Alkyl, -C 1-8 Alkoxy and -C 3 -C 8 Each of the cycloalkyl groups is optionally substituted with at least one selected from halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 aryl or 5- to 12-membered heteroaryl substituents;

[0042] R 4 is oxo (=O) or thio (=S); or

[0043] R 3 and R 4 Together with the atoms to which they are attached, they form a 5- to 6-membered aromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 3a replace;

[0044] R 3a are independently selected from hydrogen, halogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, -C 3 -C 8 Cycloalkyl or -CN, where -C 1-8 Alkyl, -C 1-8 Alkoxy and -C 3 -C 8 Each of the cycloalkyl groups is optionally substituted with at least one selected from halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8Cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 aryl or 5- to 12-membered heteroaryl substituents;

[0045] R 5 It is C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, -COR 5a , -CO 2 R 5a 、-CONR 5a R 5b , where C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 5c replace;

[0046] R 5a and R 5b Each independently selected from -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 5d replace; or

[0047] R 5a and R 5b Together with the atoms to which they are attached, they form a 3- to 8-membered unsaturated or saturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 5d replace;

[0048] R 5c and R 5d is independently selected at each occurrence from hydrogen, halogen, -C 1-8 Alkyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR5e 、-SR 5e 、-CN、-COR 5e , -CO 2 R 5e 、-CONR 5e R 5f 、-NR 5e R 5f 、-NR 5e COR 5f or -NR 5e CO 2 R 5f ;-C 1-8 Alkyl, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 5g replace;

[0049] R 5e and R 5f are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 5h replace;

[0050] R 5g and R 5h are independently selected from halogen, -OH, -CN, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0051] R 6 H, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -OR 6a 、-NR 6a R 6b 、-COR 6a , -CO 2 R 6a 、-CONR 6a R 6b 、-COR 6a or -NR 6a COR 6b , -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 6c replace;

[0052] R 6a and R 6b are each independently selected from hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 6dreplace;

[0053] R 6c is independently at each occurrence hydrogen, halogen, -C 1-8 Alkyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl 5- to 12-membered heteroaryl, oxo (=O), -OR 6e 、-SR 6e 、-CN、-COR 6e , -CO 2 R 6e 、-CONR 6e R 6f 、-NR 6e R 6f 、-NR 6e COR 6f or -NR 6e CO 2 R 6f ;-C 1-8 Alkyl, C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 6g replace;

[0054] R 6e and R 6f are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 3 -C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0055] R 6d and R 6g are independently selected from halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8Cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0056] R 7 and R 8 each independently is hydrogen;

[0057] R 9 and R 10 are each independently selected from H, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 9a replace; and

[0058] R 9a is independently at each occurrence halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl.

[0059] Aspect 2. The compound according to Aspect 1, wherein the compound is selected from Formula (IIa)-(IIp):

[0060]

[0061]

[0062]

[0063] Among them, R 1 , R 2 , R 3 , R 4, R 5 , R 6 , R 7 , R 8 , Cy3, n1, n2, n3, n6 and X 1 As defined in aspect 1.

[0064] Aspect 3. The compound according to Aspect 1, wherein the compound is selected from Formula (IIf1)-(IIf2):

[0065]

[0066] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy3, n1, n2, n3, n6 and X 1 As defined in aspect 1.

[0067] Aspect 4. The compound according to Aspect 1, wherein the compound is selected from Formula (IIIa)-(IIIb):

[0068]

[0069] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy1, Cy2, Cy3, n1, n2, n3, n6, R 9 and R 10 As defined in aspect 1.

[0070] Aspect 5. The compound according to Aspect 1, wherein the compound is selected from Formula (IVa)-(IVb):

[0071]

[0072] Among them, X 1 , R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , Cy1, Cy2, Cy3, n1, n2, n3, n6, R 9 and R10 As defined in aspect 1.

[0073] Aspect 6. The compound according to Aspect 1, wherein the compound is selected from Formula (Va)-(Vc):

[0074]

[0075]

[0076]

[0077] Among them, X 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy1, Cy2, Cy3, n3, n6, R 9 and R 10 As defined in aspect 1.

[0078] Aspect 7. The compound according to aspect 1, wherein the compound is VIa,

[0079]

[0080] Preferably, the compound is selected from VIb and Vic

[0081]

[0082]

[0083] Among them, X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy1, Cy2, Cy3, n2, n3, n6, R 11a , R 11b , R 12a , R 12b , R 13 , R 14a , R 14b , n11, n12 and n14 are as defined in Aspect 1.

[0084] Aspect 8. The compound according to aspect 1, wherein the compound is VIIa or VIIb,

[0085]

[0086] Preferably, the compound is selected from VIIc, VIId, VIIe, VIIf, VIIg or VIIh,

[0087]

[0088]

[0089] Among them, X 2 , R 2a , R 3 , R 5 , R 6 , R 9 , R 10 , Cy1, Cy2, Cy3, n2, n3, n6, R 11a , R 11b , R 12a , R 12b , R 13 , R 14a , R 14b , n11, n12 and n14 are as defined in Aspect 1.

[0090] Aspect 9. A compound as described in any of the preceding aspects, wherein Cy1 is a 5-membered or 6-membered aromatic ring containing 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with 0, 1, 2 or 3 substituents R 3 replace;

[0091] Preferably, Cy1 is phenyl, pyridyl, thienyl, imidazolyl, furanyl or pyrazolyl; each of phenyl, pyridyl, thienyl, imidazolyl, furanyl or pyrazolyl is optionally substituted by 0, 1 or 2 substituents R 3 replace.

[0092] Aspect 10. A compound as described in any of the preceding aspects, wherein Cy2 is a 4-membered, 5-membered, 6-membered, 7-membered or 8-membered saturated or partially or fully unsaturated ring, the ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen or oxygen; the ring is substituted by at least one substituent R 1 and / or R 2 replace;

[0093] Preferably, Cy2 is a 5-, 6- or 7-membered saturated or partially or fully unsaturated ring, the ring containing 0, 1 or 2 heteroatoms independently selected from nitrogen or oxygen; the ring is substituted by at least one substituent R 1 and / or R2 replace.

[0094] Aspect 11. A compound as described in any of the preceding aspects, wherein Some selected from:

[0095] Aspect 12. A compound as described in any of the preceding aspects, wherein Cy3 is a 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, 10-membered, 11-membered or 12-membered saturated or partially or fully unsaturated ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is optionally substituted by 0, 1, 2, 3, 4 or 5 substituents R 6 replace;

[0096] Preferably, Cy3 is a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11- or 12-membered saturated or partially or fully unsaturated ring, which is a monocyclic, bicyclic or tricyclic ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is optionally substituted by 0, 1, 2, 3, 4 or 5 substituents R 6 replace;

[0097] More preferably, Part is

[0098] Even more preferably, Part is

[0100] Aspect 13. A compound as described in any of the preceding aspects, wherein R 1 Independently selected from H,

[0101] Where R 11a , R 11b , R 12a , R 12b , R 13 , n11 and n12 are as defined in aspect 1.

[0102] Aspect 14. A compound as described in any of the preceding aspects, wherein R 15 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, -CN, -OR 15a 、-NR 15a R15b or -NR 15a COR 15b ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and 3- to 8-membered heterocyclic groups are each optionally substituted with at least one substituent R 15c replace;

[0103] R 15a and R 15b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C 6 -C 12 aryl or 5- to 12-membered heteroaryl, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 15d replace;

[0104] R 15c and R 15d is independently at each occurrence -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 3 -C 8 halogenated cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

[0105] Aspect 15. A compound as described in any of the preceding aspects, wherein R 15is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, -CN, -OH, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy;

[0106] Preferably, R 15 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl;

[0107] More preferably, R 15 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl;

[0108] Even more preferably, R 15 Selected from hydrogen.

[0109] Aspect 16. A compound as described in any of the preceding aspects, wherein R 11a , R 11b , R 12a and R 12beach independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1 -enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-ynyl yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl , oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN;methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-1 , hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl , oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl are each optionally substituted with at least one substituent R; 11e replace;

[0110] R 11eand -1-en-1-yl, -4-en-1-yl, -3-en-1-yl, -2-en-1-yl, -1-en-1-yl, -5 ... 1-enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1 -yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, alkynyl, oct-3-ynyl, oct-2-ynyl, oct-1-ynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxo (=O), -OR 11g , thio (=S), -SR 11g 、-CN、-SO 2 R 11g 、-SO 2 NR 11g R 11h 、-COR 11g , -CO 2 R 11h 、-CONR 11g R 11h 、-NR 11g R 11h 、-NR 11g COR 11h 、-NR 11g CO 2 R 11h or -NR 11gSO 2 R 11h ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en- yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent- 3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl, Each of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl is optionally substituted with at least one substituent R 11i replace;

[0111] R 11c , R 11d , R 11g and R 11h are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Each of alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 11j replace;

[0112] R 11i and R 11j is independently at each occurrence -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1 -yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1 -alkyn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 3 -C 8 halocycloalkyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1 -yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1 -alkyn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 3 -C 8 Each of the halocycloalkyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl is optionally substituted with at least one -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 3 -C 8 The alkylene group is substituted with a halogenated cycloalkyl group, a 3- to 8-membered heterocyclyl group, a phenyl group, or a 5- to 12-membered heteroaryl group.

[0113] Aspect 17. A compound as described in any one of the preceding aspects, wherein R 11a , R11b , R 12a and R 12beach independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1 -enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-ynyl yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl , oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN;methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-1 , hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl , oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl are each optionally substituted with at least one substituent R; 11e replace;

[0114] R 11eis, independently at each occurrence, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl. 1-enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1- yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, yl, oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, -OR 11g or -CN;

[0115] R 11g independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl;

[0116] Preferably, R 11a , R 11b , R 12a and R 12b Each independently selected from H, -CH 3 , -CF 3 、-CH 2 CH 3 、-CH 2 CF 3, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyrrolidinyl, tetrahydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, benzyl, vinyl, propenyl, allyl, but-3-en-1-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl,

[0117] Aspect 18. A compound as described in any one of the preceding aspects, wherein (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R 12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6- or 8-membered unsaturated or saturated ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 11f replace;

[0118] R 11f is independently at each occurrence hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR 11g , thio (=S), -SR 11g 、-CN、-SO 2 R 11g 、-SO 2 NR 11g R 11h 、-COR 11g , -CO 2 R 11h 、-CONR 11g R 11h 、-NR 11g R 11h 、-NR 11g COR 11h、-NR 11g CO 2 R 11h or -NR 11g SO 2 R 11h ;

[0119] R 11g and R 11h are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0120] R 11i is independently at each occurrence -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 3 -C 8 Halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 Aryl or 5- to 12-membered heteroaryl;

[0121] Preferably, (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R 12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the carbon atoms to which they are attached, form a 3-, 4-, 5-, 6- or 8-membered unsaturated or saturated ring;

[0122] More preferably, (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, or 8-membered saturated ring.

[0123] Aspect 19. A compound as described in any one of the preceding aspects, wherein R 13 , R 14a and R 14b R is each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or 3-8 membered heterocyclyl; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or 3-8 membered heterocyclyl is optionally substituted by at least one substituent R 13a replace;

[0124] R 13a is independently at each occurrence halogen, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 3 -C 8 Halogenated cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl;

[0125] Preferably, R 13 , R 14a and R 14b Each is independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or a 3- to 8-membered heterocyclyl;

[0126] More preferably, R 13 is hydrogen, methyl, ethyl, propyl or butyl; R 14a and R 14b Each is independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or a 3- to 8-membered heterocyclyl;

[0127] Even more preferably, R 13 is hydrogen; R 14a and R14b Each is independently selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, and cyclopentyl.

[0128] Aspect 20. A compound as described in any of the preceding aspects, wherein R 1 Selected from

[0130] Aspect 21. A compound as described in any of the preceding aspects, wherein R 2 independently selected from H, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -CN, -COR 2a , -CO 2 R 2a 、-CONR 2a R 2b 、-NR 2a R 2b 、-NR 2a COR 2b , methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl and imidazopyridinyl is optionally substituted with at least one substituent R 2c replace;

[0131] R 2a and R 2b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, is optionally substituted with at least one substituent R 2d replace; or

[0132] R 2a and R 2b Together with the carbon atoms to which they are attached, they form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2d replace;

[0133] R 2c and R 2d is independently at each occurrence hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, oxo (=O), -OR 2e 、-SR 2e 、-CN、-COR 2e , -CO 2 R 2e 、-CONR 2e R 2f 、-NR 2e R 2f 、-NR 2e COR 2f or -NR 2e CO 2 R 2f; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, each of which is optionally substituted with at least one substituent R 2g replace;

[0134] R 2e and R 2f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 2h replace;

[0135] R 2g and R 2h is independently at each occurrence -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 Halogenated alkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 3 -C 8 halogenated cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

[0136] Aspect 22. A compound as described in any of the preceding aspects, wherein R 2independently selected from H, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -CN, -COR 2a , -CO 2 R 2a or-CONR 2a R 2b , methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, each of which is optionally substituted with at least one substituent R 2c replace;

[0137] R 2a and R 2b each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl; methyl, Each of ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, is optionally substituted with at least one substituent R 2d replace; or

[0138] R 2a and R 2b Together with the carbon atoms to which they are attached, they form a 3-, 4-, 5- or 6-membered unsaturated or saturated ring containing 0 or 1 heteroatom independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2d replace;

[0139] R 2c and R 2dis independently at each occurrence hydrogen (H or D), -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -OR 2e , -CN or -NR 2e R 2f methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, each of which is optionally substituted with at least one substituent R 2g replace;

[0140] R 2e and R 2f R is each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl is optionally substituted with at least one substituent R 2h replace;

[0141] R 2g and R 2h is independently at each occurrence -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;

[0142] Preferably, R 2 yes

[0143]

[0144] -CH 3 ,

[0145] Aspect 23. A compound as described in any of the preceding aspects, wherein R 3are independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl is optionally replaced by at least one selected from -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 aryl or 5- to 12-membered heteroaryl substituents;

[0146] Preferably, R 3 are independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or -CN;

[0147] More preferably, R 3 Independently selected from hydrogen, -F, -Cl, -Br, -I.

[0148] Aspect 24. A compound as described in any of the preceding aspects, wherein R 4 It is an oxo group (=O).

[0149] Aspect 25. A compound as described in any of the preceding aspects, wherein R 3 and R 4 Together with the carbon atoms to which they are attached, they form a 5- to 6-membered aromatic ring, the ring containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 3a replace;

[0150] R 3aare independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl is optionally replaced by at least one selected from -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, -C 6 -C 12 The substituents are substituted by aryl or 5- to 12-membered heteroaryl.

[0151] Aspect 26. A compound as described in any of the preceding aspects, wherein R 5 is phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -COR 5a , -CO 2 R 5a or-CONR 5a R 5b , wherein each of phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5c replace;

[0152] R 5a and R 5b Each is independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, oxadiazolyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, oxadiazolyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5d replace; or

[0153] R 5a and R 5b Together with the nitrogen atom to which they are attached, they form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 5d replace;

[0154] R 5c and R 5d is independently selected at each occurrence from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, oxo (=O), -OR 5e 、-SR 5e 、-CN、-COR 5e , -CO 2 R 5e 、-CONR 5e R 5f 、-NR 5e R 5f 、-NR 5e COR 5f or -NR 5e CO 2 R 5f; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl each optionally substituted with at least one substituent R 5g replace;

[0155] R 5e and R 5f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5h replace;

[0156] R 5g and R 5h are each independently selected from halogen, -OH, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

[0157] Aspect 27. A compound as described in any of the preceding aspects, wherein R 5 is pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl, wherein each of the pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl and imidazopyridinyl groups is optionally substituted with at least one substituent R 5c replace;

[0158] R 5c is independently selected at each occurrence from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl;

[0159] Preferably, R 5 is benzoxazolyl;

[0160] More preferably, R 5 yes

[0161] Aspect 28. A compound as described in any of the preceding aspects, wherein R 5 Yes-COR 5a , -CO 2 R 5a or-CONR 5a R 5b ;

[0162] Where R 5a and R 5b each independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, oxadiazolyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; Each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5d replace;

[0163] R 5d is independently selected at each occurrence from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -OR 5e or -CN; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5g replace;

[0164] R 5e is selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; ... Each of phenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5h replace;

[0165] R 5g and R 5h each independently selected from halogen, -OH, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, or 5- to 12-membered heteroaryl;

[0166] Preferably, R 5 yes

[0167] -COCH 3 or -COCF 3 .

[0168] Aspect 29. A compound as described in any of the preceding aspects, wherein R 6 is H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN, -OR 6a 、-NR 6a R 6b 、-COR 6a , -CO 2 R 6a 、-CONR 6a R 6b 、-COR 6a or -NR 6a COR 6b , methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl is optionally substituted with at least one substituent R 6c replace;

[0169] R 6a and R 6b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 6d replace;

[0170] R 6cis independently at each occurrence hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, oxo (=O), -OR 6e 、-SR 6e 、-CN、-COR 6e , -CO 2 R 6e 、-CONR 6e R 6f 、-NR 6e R 6f 、-NR 6e COR 6f or -NR 6e CO 2 R 6f ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, each of which is optionally substituted with at least one substituent R 6g replace;

[0171] R 6e and R 6f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl;

[0172] R 6d and R 6g each independently selected from -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

[0173] Aspect 30. A compound as described in any of the preceding aspects, wherein R 6H, -F, -Cl, -Br, -I, methyl, -CF 3 , ethyl, -CH 2 CF 3 , -CF 2 CH 3 , propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy,

[0174] Preferably, Part is

[0175]

[0176] Aspect 31. A compound as described in any of the preceding aspects, wherein R 9 and R 10 Each is independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl or 5- to 12-membered heteroaryl, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 9a replace;

[0177] R 9a is independently at each occurrence halogen, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl;

[0178] Preferably, R 9 and R 10Each is independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl or 5- to 12-membered heteroaryl;

[0179] More preferably, R 9 and R 10 Each is independently selected from H, methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl;

[0180] More preferably, R 9 and R 10 Each is independently selected from H and cyclopropyl.

[0181] Aspect 32. A compound as described in any of the preceding aspects, wherein the compound is selected from

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201] Aspect 33. A pharmaceutical composition comprising a compound according to any one of Aspects 1 to 32 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, and a pharmaceutically acceptable excipient.

[0202] Aspect 34. A method of reducing IL-17 activity by inhibition, comprising administering to a subject a compound as described in any one of Aspects 1 to 32, or a pharmaceutically acceptable salt thereof, including a compound of formula (I) or a specific compound exemplified herein.

[0203] Aspect 35. The method of Aspect 34, wherein the disease is selected from cancer.

[0204] Aspect 36. Use of a compound according to any one of Aspects 1 to 32, or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, in the preparation of a medicament for treating a disease that can be affected by IL-17.

[0205] Aspect 37. The use according to Aspect 36, wherein the disease is an autoimmune disease or an inflammatory disease.

[0206] Aspect 38. The use according to Aspect 37, wherein the disease is chronic inflammation, psoriasis, spondyloarthritis, rheumatoid arthritis or multiple sclerosis. DETAILED DESCRIPTION

[0207] The following terms have the indicated meanings throughout the specification:

[0208] As used herein, including the appended aspects, singular forms of words such as "a / an" and "the" include their corresponding plural references unless the context clearly dictates otherwise.

[0209] Unless the context clearly dictates otherwise, the term "or" is used to mean, and is used interchangeably with, the term "and / or."

[0210] The term "alkyl" refers to a hydrocarbon group selected from straight and branched saturated hydrocarbon groups containing 1 to 18, such as 1 to 12, further such as 1 to 10, further such as 1 to 8, or 1 to 6 or 1 to 4 carbon atoms. 1-6Examples of alkyl) include, but are not limited to, methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or sec-butyl ("s-Bu"), 1,1-dimethylethyl or tert-butyl ("t-Bu"), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.

[0211] The term "cycloalkyl" refers to a hydrocarbon group selected from saturated cyclic hydrocarbon groups, including monocyclic and polycyclic (eg, bicyclic and tricyclic) groups, including fused, bridged or spiro cycloalkyl groups.

[0212] The term "aryl", used alone or in combination with other terms, refers to a group selected from:

[0213] 5- and 6-membered carbocyclic aromatic rings, e.g., phenyl;

[0214] Bicyclic ring systems, such as 7- to 12-membered bicyclic ring systems in which at least one ring is carbocyclic and aromatic, for example, naphthyl and indanyl; and

[0215] A tricyclic ring system, such as a 10- to 15-membered tricyclic ring system, wherein at least one ring is carbocyclic and aromatic, for example, fluorenyl.

[0216] The terms "aromatic hydrocarbon ring" and "aryl" are used interchangeably throughout the disclosure herein. In some embodiments, the monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring carbon atoms (i.e., C 5-10 Examples of monocyclic or bicyclic aromatic hydrocarbon rings include, but are not limited to, phenyl, naphthalene-1-yl, naphthalene-2-yl, anthracenyl, phenanthrenyl, etc. In some embodiments, the aromatic hydrocarbon ring is a naphthalene ring (naphthalene-1-yl or naphthalene-2-yl) or a phenyl ring. In some embodiments, the aromatic hydrocarbon ring is a phenyl ring.

[0217] The term "aryl-alkyl-" refers to an alkyl group as defined above that is further substituted with an aryl group. Examples of aryl-alkyl groups include aryl-C 1-8 Alkyl, such as phenylethyl or phenylmethyl (benzyl).

[0218] The term "heteroaryl" refers to a group selected from:

[0219] A 5-, 6-, or 7-membered aromatic monocyclic ring comprising at least one heteroatom selected from nitrogen (N), sulfur (S), and oxygen (O), for example, 1 to 4 (or in some embodiments, 1 to 3, in some embodiments, 1 to 2) heteroatoms, the remaining ring atoms being carbon;

[0220] 7- to 12-membered bicyclic rings comprising at least one heteroatom selected from N, O and S, e.g., 1 to 4 (or in some embodiments, 1 to 3, or in other embodiments, 1 or 2) heteroatoms, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring; and

[0221] An 11- to 14-membered tricyclic ring comprising at least one heteroatom selected from N, O and S, e.g., 1 to 4 (or in some embodiments, 1 to 3, or in other embodiments, 1 or 2) heteroatoms, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.

[0222] When the total number of S and O atoms in the heteroaryl exceeds 1, those heteroatoms are not adjacent to each other. In some embodiments, the total number of S and O atoms in the heteroaryl does not exceed 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle does not exceed 1. When the heteroaryl contains more than one heteroatom ring member, the heteroatoms can be the same or different. The nitrogen atoms in one or more rings of the heteroaryl can be oxidized to form N-oxides. As used herein, the term "C-attached heteroaryl" means that the heteroaryl is attached to the core molecule via a bond from a C-atom of the heteroaryl ring.

[0223] The terms "aromatic heterocycle" and "heteroaryl" are used interchangeably throughout the disclosure herein. In some embodiments, the monocyclic or bicyclic aromatic heterocycle has 5, 6, 7, 8, 9 or 10 ring members, wherein 1, 2, 3 or 4 heteroatom ring members are independently selected from nitrogen (N), sulfur (S) and oxygen (O) and the remaining ring members are carbon. In some embodiments, the monocyclic or bicyclic aromatic heterocycle is a monocyclic or bicyclic ring containing 1 or 2 heteroatom ring members independently selected from nitrogen (N), sulfur (S) and oxygen (O). In some embodiments, the monocyclic or bicyclic aromatic heterocycle is a 5 to 6-membered heteroaryl ring, which is monocyclic and has 1 or 2 heteroatom ring members independently selected from nitrogen (N), sulfur (S) and oxygen (O). In some embodiments, the monocyclic or bicyclic aromatic heterocycle is an 8- to 10-membered heteroaryl ring that is bicyclic and has 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur, and oxygen.

[0224] "Heterocyclyl", "heterocycle" or "heterocyclic" are interchangeable and include non-aromatic heterocyclic groups containing one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members, the remaining ring members being carbon, including monocyclic, fused, bridged and spirocyclic rings, i.e., containing monocyclic heterocyclic groups, bridged heterocyclic groups, spiro heterocyclic groups and fused heterocyclic groups. The term "optionally oxidized sulfur" as used herein refers to S, SO or SO 2 .

[0225] The compounds disclosed herein may contain asymmetric centers and therefore may exist as enantiomers. "Enantiomers" refer to two stereoisomers of a compound that are non-superimposable mirror images of each other. In the case where the compounds disclosed herein have two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers belong to a wider class of stereoisomers. It is intended to include all such possible stereoisomers in the form of substantially pure resolved enantiomers, racemic mixtures thereof, and mixtures of diastereomers. All stereoisomers of the compounds disclosed herein and / or their pharmaceutically acceptable salts are intended to be included. Unless otherwise specifically noted, a reference to an isomer is applicable to any possible isomer. As long as the isomer composition is not specified, all possible isomers are included.

[0226] As used herein, the term "substantially pure" means that the target stereoisomer contains no more than 35%, such as no more than 30%, further such as no more than 25%, even further such as no more than 20% of any other stereoisomer by weight. In some embodiments, the term "substantially pure" means that the target stereoisomer contains no more than 10%, such as no more than 5%, such as no more than 1% of any other stereoisomer by weight.

[0227] Unless stated otherwise, when compounds disclosed herein contain olefinic double bonds, such double bonds are intended to include both E and Z geometric isomers.

[0228] When the compounds disclosed herein contain disubstituted cyclohexyl or cyclobutyl, the substituents found on the cyclohexyl or cyclobutyl ring can take cis and trans forms. The cis form means that both substituents are located on the upper side of the 2 substituent positions on the carbon, while the trans form means that they are located on the opposite side.

[0229] It may be advantageous to separate the reaction products from each other and / or from the starting materials. The desired products of each step or series of steps are separated and / or purified (hereinafter separated) to the desired degree of homogeneity by techniques commonly used in the art. Typically, such separations include multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography may involve any number of methods, including, for example: reverse phase and normal phase chromatography; size exclusion chromatography; ion exchange chromatography; high pressure, medium pressure, and low pressure liquid chromatography methods and apparatus; small scale analytical chromatography; simulated moving bed ("SMB") chromatography and preparative thin or thick layer chromatography, as well as small scale thin layer and flash chromatography techniques. Those skilled in the art will apply the techniques that are most likely to achieve the desired separation. "Diastereoisomers" refer to stereoisomers of compounds having two or more chiral centers but not mirror images of each other. Based on their physicochemical differences, diastereomeric mixtures can be separated into their individual diastereomers by methods well known to those skilled in the art, such as by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Enantiomers can also be separated by using a chiral HPLC column.

[0230] "Pharmaceutically acceptable salts" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting a free base functional group with a suitable organic acid or by reacting an acidic group with a suitable base.

[0231] In addition, if the compounds disclosed herein are obtained as acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, an addition salt (such as a pharmaceutically acceptable addition salt) can be prepared by conventional methods for preparing acid addition salts from base compounds, by dissolving the free base in a suitable organic solvent and / or water and treating the solution with an acid. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts without undue experimentation.

[0232] As defined herein, "pharmaceutically acceptable salts thereof" include salts of at least one compound of formula (I) and salts of stereoisomers of compounds of formula (I), such as enantiomeric salts and / or diastereomeric salts.

[0233] As used herein, the terms "administration," "administering," "treating," and "treatment" refer to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, a human, a subject, a cell, a tissue, an organ, or a biological fluid. Treatment of cells encompasses contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. The terms "administering" and "treatment" also refer to in vitro and ex vivo treatment of a cell, for example, by an agent, a diagnostic agent, a binding compound, or by another cell. The term "subject" herein includes any organism, preferably an animal, more preferably a mammal (e.g., rats, mice, dogs, cats, and rabbits), and most preferably a human.

[0234] The term "effective amount" or "therapeutically effective amount" refers to an amount of an active ingredient (such as a compound) that is sufficient to affect the treatment of a disease, disorder or symptom when administered to a subject to treat a disease, or at least one clinical symptom of a disease or condition. The term "therapeutically effective amount" may vary with the compound, the disease, disorder, and / or the symptoms of the disease or condition, the severity of the disease, disorder and / or the symptoms of the disease or condition, the age of the subject to be treated, and / or the weight of the subject to be treated. In any given case, the appropriate amount may be obvious to those skilled in the art, or may be determined by routine experimentation. In some embodiments, a "therapeutically effective amount" is the amount of at least one compound disclosed herein and / or at least one stereoisomer thereof and / or at least one pharmaceutically acceptable salt thereof that is effective in "treating" a disease or condition as defined above in a subject. In the case of combination therapy, a "therapeutically effective amount" refers to the total amount of a combination object used to effectively treat a disease, disorder or illness.

[0235] The pharmaceutical composition comprising the compounds disclosed herein can be administered to a subject in need thereof via oral, inhalation, rectal, parenteral or topical administration. For oral administration, the pharmaceutical composition can be a conventional solid preparation, such as a tablet, powder, granule, capsule, etc.; a liquid preparation, such as water or oil suspension; or other liquid preparations, such as syrups, solutions, suspensions, etc.; for parenteral administration, the pharmaceutical composition can be a solution, an aqueous solution, an oil suspension concentrate, a lyophilized powder, etc. Preferably, the dosage form of the pharmaceutical composition is selected from tablets, coated tablets, capsules, suppositories, nasal sprays or injections, more preferably tablets or capsules. The pharmaceutical composition can be a single unit administration using an accurate dose. In addition, the pharmaceutical composition may also include additional active ingredients.

[0236] All preparations of the pharmaceutical composition disclosed herein can be prepared by conventional methods in the pharmaceutical field. For example, the active ingredient can be mixed with one or more excipients, and then the desired preparation is prepared. "Pharmaceutically acceptable excipient" refers to conventional pharmaceutical carriers suitable for the desired pharmaceutical preparation, for example: diluents; vehicles, such as water, various organic solvents, etc.; fillers, such as starch, sucrose, etc.; binders, such as cellulose derivatives, alginates, gelatin and polyvinyl pyrrolidone (PVP); wetting agents, such as glycerol; disintegrants, such as agar, calcium carbonate and sodium bicarbonate; absorption enhancers, such as quaternary ammonium compounds; surfactants, such as hexadecanol; absorption carriers, such as kaolin and bentonite; lubricants, such as talc, calcium stearate, magnesium stearate, polyethylene glycol, etc. In addition, the pharmaceutical composition also includes other pharmaceutically acceptable excipients, such as dispersants, stabilizers, thickeners, complexing agents, buffers, penetration enhancers, polymers, fragrances, sweeteners and dyes.

[0237] The term "disease" refers to any illness, ailment, ailment, symptom, or indication, and is interchangeable with the terms "disorder" or "condition."

[0238] In this specification and subsequent aspects, unless the context requires otherwise, the term "comprise" and variations such as "comprises" and "comprising" are intended to specify the presence of the following features, but do not exclude the presence or addition of one or more other features. When used herein, the term "comprises" can be replaced by the terms "contains", "includes" or sometimes "has".

[0239] Throughout this specification and the following aspects, the term "C n-m " denotes a range including endpoints, wherein n and m are integers and represent the number of carbons. Examples include C 1-8 , C 1-6 wait.

[0240] Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0241] Example

[0242] The present invention is further illustrated by the following examples which illustrate the invention but are not limited thereto.

[0243] In the following examples, the following abbreviations are used:

[0244] AcOH or HOAc Acetic acid

[0245] aq. Aqueous solution

[0246] BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl)

[0247] BH 3 Borane

[0248] Brine saturated sodium chloride aqueous solution

[0249] Boc 2 O Di-tert-butyl carbonate

[0250] BSA bovine serum albumin

[0251] CDI 1,1'-Carbonyldiimidazole

[0252] DAST Diethylaminosulfur trifluoride

[0253] DBN 1,5-diazabicyclo[4.3.0]non-5-ene

[0254] DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

[0255] DCE 1,2-Dichloroethane

[0256] DCM Dichloromethane

[0257] DMAP 4-dimethylaminopyridine

[0258] CH 3 MgBr Methylmagnesium bromide

[0259] DIPEA N,N-Diisopropylethylamine

[0260] DMF N,N-Dimethylformamide

[0261] DMAC Dimethylacetamide

[0262] DMSO Dimethyl sulfoxide

[0263] DPPA Diphenylphosphoryl azide

[0264] EA Ethyl acetate

[0265] EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride

[0266] EDTA Ethylenediaminetetraacetic acid

[0267] EtOH

[0268] h or hr hour

[0269] HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- Oxide hexafluorophosphate Hex

[0270] 1 H NMR Proton nuclear magnetic resonance

[0271] H 2 O 2 Hydrogen Peroxide

[0272] HOBt Hydroxybenzotriazole

[0273] IPA(i-PrOH) Isopropyl alcohol

[0274] KOAc Potassium acetate

[0275] LAH Lithium Aluminum Hydride

[0276] LC-MS liquid chromatography-mass spectrometry

[0277] LDA Lithium diisopropylamide

[0278] MeOH Methanol

[0279] MsOH Methanesulfonic acid

[0280] Min Minutes

[0281] n-BuLi n-butyllithium

[0282] NaH Sodium hydride

[0283] NaBH(OAc) 3 Sodium triacetoxyborohydride

[0284] (STAB)

[0285] NaBH 3 CN Sodium cyanoborohydride

[0286] NH 4 Cl Ammonium chloride

[0287] Pd / C Palladium / Carbon Powder

[0288] Pd(dppf)Cl 2 [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)

[0289] Pd(PPh 3 ) 4 Tetrakis(triphenylphosphine)palladium(0)

[0290] Pd(OAc) 2 Palladium acetate

[0291] Pd(OH) 2 / C Palladium hydroxide / carbon powder

[0292] PE Petroleum Ether

[0293] pH -lg (hydrogen ion concentration)

[0294] Preparative HPLC Preparative High Pressure Liquid Chromatography

[0295] Preparative MPLC Preparative Medium Pressure Liquid Chromatography

[0296] Preparative SFC Preparative Supercritical Fluid Chromatography

[0297] Preparative TLC Preparative Thin Layer Chromatography

[0298] p-TsOH p-Toluenesulfonic acid

[0299] rt or RT Room temperature

[0300] sat. saturated

[0301] t-BuOK Potassium tert-butoxide

[0302] TBS tert-Butyldimethylsilyl

[0303] THF Tetrahydrofuran

[0304] TEA Triethylamine

[0305] TFA Trifluoroacetic acid

[0306] TsCl 4-Toluenesulfonyl chloride

[0307] TMSCN Trimethylsilyl cyanide

[0308] TMSCF 3 (Trifluoromethyl)trimethylsilane

[0309] TBAF Tetrabutylammonium fluoride

[0310] TBSOTf tert-Butyldimethylsilyl trifluoromethanesulfonate

[0311] TiCl 4 Titanium Tetrachloride

[0312] TIPT Propylphosphonic Anhydride Solution

[0313] TMSI Trimethylsilyl iodide

[0314] The following examples are intended to be exemplary only and should not be construed as limiting in any way. Efforts have been made to ensure accuracy with respect to the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be considered. Unless otherwise indicated, temperatures are in degrees Celsius. Reagents were purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, or TCI, and were used without further purification unless otherwise indicated.

[0315] Unless otherwise indicated, the reactions described below were performed under a positive pressure of nitrogen or argon or with a drying tube in anhydrous solvents; reaction flasks were equipped with rubber septa for introduction of substrates and reagents via syringe; and glassware was oven-dried and / or heat-dried.

[0316] Recorded on an Agilent instrument operating at 400 MHz 1 H NMR spectrum. Using CDCl 3 , CD 2 Cl 2 , CD 3 OD,D 2 O、d 6 -DMSO, d 6 -Acetone or (CD 3 ) 2 CO was used as solvent, and tetramethylsilane (0.00 ppm) or residual solvent (CDCl 3 :7.25ppm;CD 3 OD: 3.31ppm; D 2 O: 4.79ppm; d 6 -DMSO: 2.50ppm; d6-acetone: 2.05; (CD 3 ) 2 CO: 2.05) as the reference standard, and 1 HNMR spectra. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), sx (sextet), m (multiplet), br (broad), dd (double of doublets), dt (double of triplets). Coupling constants, when given, are reported in Hertz (Hz).

[0317] LC-MS spectrometer (Agilent 1260) Detector: MWD (190-400nm), mass detector: 6120SQ

[0318] Mobile phase: A: acetonitrile containing 0.1% formic acid, B: water containing 0.1% formic acid

[0319] Column: Poroshell 120EC-C18, 4.6×50 mm, 2.7 μm

[0320] Gradient method: Flow rate: 1.8 mL / min

[0321]

[0322]

[0323] The HPLC was carried out at room temperature with UV detection at 214 nm and 254 nm on columns (150 × 21.2 mm ID, 5 μm, Gemini NX-C18) and (150 × 19 mm, 5 μm, SunFire Prep C18 OBD TM ) at different flow rates and injection volumes.

[0324] Combi Flash chromatography was performed on a column (C18 spherical 20-35 μm) at room temperature with UV detection at 214 nm and 254 nm at different flow rates and injection volumes.

[0325] Preparation of intermediate (Int):

[0326] Int A1: 5-((S)-2-amino-2-cyclohexylacetylamino)-N-methyl-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2-carboxamide

[0327] Step 1: 2-Amino-N-methyl-2,3-dihydro-1H-indene-2-carboxamide

[0328]

[0329] 2-Amino-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (3.8 g, 20 mmol) was dissolved in MeNH 2 The mixture in solution (33%, wt. in EtOH, 20 mL) was heated to 80°C in a sealed tube for 4 hours. The reaction was cooled to ambient temperature and concentrated in vacuo to afford the title compound (3.7 g, yield: 97.32%).

[0330] Step 2: 2-amino-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide

[0331]

[0332] At 0°C, H 2 SO 4 (3 mL) and HNO 32-Amino-N-methyl-2,3-dihydro-1H-indene-2-carboxamide (3.7 g, 19.46 mmol, solution in 6 mL HOAc) was slowly added portionwise to the mixture of 4% paraformaldehyde (2.5% paraformaldehyde, 1.1% paraformaldehyde, 1.3% paraformaldehyde, 1.6% paraformaldehyde, 1.7% paraformaldehyde, 1.2 ... 3 The product was added into a 4% flask (1% pyrrolidone) and stirred for 2 h at 4 0 ℃ for 1 h. The mixture was stirred for 2 h at 4 0 ℃ for 30 0 s. Solution (aqueous solution, 200 mL) and then diluted with DCM (200 mL). The organic layer was separated, dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 20 / 0 to 20 / 1) to give the title compound (3.28 g, yield: 71.56%).

[0333] Step 3: tert-Butyl (2-(methylcarbamoyl)-5-nitro-2,3-dihydro-1H-inden-2-yl)carbamate

[0334]

[0335] 2-Amino-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide (1.18 g, 5 mmol) and Boc 2 A mixture of 1,2-dihydro-1,4-dihydro-2-nitropropene (1,15 g, 5.25 mmol) in DCM (50 mL) was stirred overnight. The mixture was quenched with brine (50 mL), separated and the organic phase was purified by Na 2 SO 4 Dry and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title product (1.31 g, yield: 77.52%). MS (ESI, m / e) [M+1] + 336.3.

[0336] Step 4: tert-Butyl (5-amino-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate

[0337]

[0338] A mixture of tert-butyl (2-(methylcarbamoyl)-5-nitro-2,3-dihydro-1H-inden-2-yl)carbamate (1.31 g, 3.90 mmol) and Pd / C (150 mg) in MeOH (50 mL) was treated with H 2 The mixture was purged with a balloon and stirred overnight. The mixture was filtered, concentrated in vacuo, and purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title product (1.06 g, yield: 88.99%). MS (ESI, m / e) [M+1] + 306.0.

[0339] Step 5: (5-((S)-2-(((benzyloxy)carbonyl)amino)-2-cyclohexylacetylamino)-2-(methylamino)methoxy tert-butyl (2,3-dihydro-1H-inden-2-yl)carbamate.

[0340]

[0341] A mixture of (S)-2-(((benzyloxy)carbonyl)amino)-2-cyclohexylacetic acid (909 mg, 3.0 mmol), tert-butyl (5-amino-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate (915 mg, 3.0 mmol), HATU (1.14 g, 3.0 mmol) and TEA (606 mg, 6.0 mmol) in DCM (100 mL) was stirred at room temperature for 4 h. The mixture was washed with NaHCO 3 The aqueous solution (150 mL) was quenched, the organic phase was separated and the 2 SO 4 Dry and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title product (1.41 g, yield: 80.67%). MS (ESI, m / e) [M+1] + 579.3.

[0342] Step 6: ((1S)-2-((2-amino-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)- Benzyl 1-cyclohexyl-2-oxoethyl)carbamate

[0343]

[0344] A mixture of tert-butyl (5-((S)-2-(((benzyloxy)carbonyl)amino)-2-cyclohexylacetamido)-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate (5 g, 8.6 mmol) in DCM (50 mL) and TFA (20 mL) was stirred at 20° C. for 2 hours. The reaction mixture was then concentrated under reduced pressure. The residue was purified by HPLC. 2 O (50 mL) and the aqueous phase was diluted with Na 2 CO 3 The mixture was basified to pH about 8-9. The mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were purified by Na 2 SO 4 Dry, filter and concentrate in vacuo to give benzyl ((1S)-2-((2-amino-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamate (4 g, crude material). MS (ESI, m / e) [M+H] + 479.3.

[0345] Step 7: ((1S)-2-((2-(((1-(((tert-butoxycarbonyl)amino)methyl)cyclopropyl)methyl)amino)-2- Benzyl (methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamate

[0346]

[0347] To a solution of benzyl ((1S)-2-((2-amino-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamate (0.8 g, 1.7 mmol) and tert-butyl ((1-formylcyclopropyl)methyl)carbamate (0.5 g, 2.5 mmol) in DCM (15 mL) at 0° C. were added AcOH (0.2 g, 3.4 mmol) and NaBH(OAc)3 (0.931 g, 4.2 mmol). The mixture was stirred at 25° C. for 3 h. The reaction mixture was then treated with NaHCO 3 The mixture was diluted with aqueous solution (20 mL) and extracted with DCM (10 mL x 3), washed with brine, and purified by Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1) to obtain the title compound (0.65 g, yield: 59%).

[0348] Step 8: ((1S)-2-((2-(((1-(aminomethyl)cyclopropyl)methyl)amino)-2-(methylcarbamoyl) (2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamic acid benzyl ester

[0349]

[0350] A mixture of benzyl ((1S)-2-((2-(((1-(((tert-butoxycarbonyl)amino)methyl)cyclopropyl)methyl)amino)-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamate (0.65 g, 0.982 mmol) in HCl / EtOAc (10 mL) was stirred at 25° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give benzyl ((1S)-2-((2-(((1-(aminomethyl)cyclopropyl)methyl)amino)-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamate (0.55 g, HCl salt). MS (ESI, m / e) [M+H] + 562.3.

[0351] Step 9: ((1S)-1-cyclohexyl-2-((2-(methylcarbamoyl)-2-(6-oxo-5,7-diazaspiro [2.5] benzyl (oct-5-yl)-2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)carbamate

[0352]

[0353] To a solution of benzyl ((1S)-2-((2-(((1-(aminomethyl)cyclopropyl)methyl)amino)-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamate (0.55 g, 0.98 mmol) in THF (10 mL) was added TEA (0.198 g, 1.9 mmol) and CDI (0.317 g, 1.9 mmol). The mixture was stirred at 60 ° C for 8 hours. The reaction mixture was poured into ice / water (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1) to give benzyl ((1S)-1-cyclohexyl-2-((2-(methylcarbamoyl)-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)carbamate (0.46 g, yield: 80%).

[0354] Step 10: 5-((S)-2-amino-2-cyclohexylacetylamino)-N-methyl-2-(6-oxo-5,7-diazaspiro [2.5] oct-5-yl)-2,3-dihydro-1H-indene-2-carboxamide (IntA1).

[0355] To a solution of benzyl ((1S)-1-cyclohexyl-2-((2-(methylcarbamoyl)-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)carbamate (0.41 g, 0.698 mmol) in MeOH (10 mL) and MeNH2.H2O (1 mL) was added Pd(OH)2 (0.1 g, 0.698 mmol). The mixture was stirred at 50°C under H 2 The reaction mixture was stirred at 40 ℃ for 1 hour under 40 ℃ of stirring (15 psi). The reaction mixture was diluted with water (5 mL) and extracted with EtOAc (5 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give 5-((S)-2-amino-2-cyclohexylacetylamino)-N-methyl-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2-carboxamide (280 mg, yield: 87%). 1 H NMR (400 MHz, DMSO-d 6)δppm:10.08-9.41(m,1H),7.50(s,1H),7.40-7.22(m,2H),7.06(d,J=8. 4Hz,1H),6.42(s,1H),3.55-3.39(m,3H),3.12-2.93(m,5H),2.91-2.81(m ,2H),2.56(d,J=4.8Hz,3H),2.00-1.81(m,1H),1.69(d,J=10.0Hz,3H),1. 62-1.45(m,3H),1.23-0.97(m,5H),0.45-0.32(m,2H),0.19-0.44(m,2H). MS(ESI,m / e)[M+H] + 454.3.

[0356] Int A2: 5-((S)-2-amino-2-cyclohexylacetylamino)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-2,3-dihydro-1H-indene-2-carboxamide

[0357] Step 1: ((2R)-3-methyl-1-((2-(methylcarbamoyl)-5-nitro-2,3-dihydro-1H-inden-2-yl) tert-Butyl amino)butan-2-yl)carbamate

[0358]

[0359] To a solution of 2-amino-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide (10 g, 42.51 mmol) and (R)-tert-butyl(3-methyl-1-oxobutan-2-yl)carbamate (15.4 g, 78.52 mmol) in MeOH (100 mL) was added NaBH 3 CN (5.17 g, 858.02 mmol). The mixture was stirred at 25 °C for 12 h. The reaction mixture was then concentrated under reduced pressure. The residue was diluted in water (50 mL) and extracted with DCM (50 mL x 3). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was analyzed by preparative MPLC (SiO 2 The product was purified by column chromatography, eluent: petroleum ether / ethyl acetate (v / v) = 10 / 1 to 0 / 1) to give tert-butyl ((2R)-3-methyl-1-((2-(methylcarbamoyl)-5-nitro-2,3-dihydro-1H-inden-2-yl)amino)butan-2-yl)carbamate (13 g, yield: 73%). 1 H NMR (400 MHz, DMSO-d 6)δppm8.08(d,J=10.0Hz,2H),7.63-7.61(m,1H),7.34(d,J=8.0Hz,1H),7.19(d,J=3.2Hz,1H),4.31(s,1H),3.70-3.59(m,3H),3.44(s, 1H),3.02-2.99(m,2H),2.88(d,J=4.8Hz,1H),2.58-2.55(m,1H),2.35-2.33(m,1H),1.68-1.66(m,2H),1.45(s,9H),0.89-0.85(m,6H).

[0360] Step 2: 2-(((R)-2-amino-3-methylbutyl)amino)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2- Formamide

[0361]

[0362] To a solution of tert-butyl ((2R)-3-methyl-1-((2-(methylcarbamoyl)-5-nitro-2,3-dihydro-1H-inden-2-yl)amino)butan-2-yl)carbamate (7.8 g, 18.55 mmol) in DCM (80 mL) was added TFA (10 mL). The mixture was stirred at 20 °C for 13 h. After concentrating to remove TFA, the reaction mixture was filtered through saturated NaHCO 3 (50 mL) was quenched and then extracted with DCM (100 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was analyzed by preparative MPLC (SiO 2 Column, eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1) to obtain 2-(((R)-2-amino-3-methylbutyl)amino)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide (4.5 g, yield: 76%). MS (ESI, m / e) [M+H] + 321.2.

[0363] Step 3: 2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-5-nitro-2,3-dihydro-1H- Indene-2-carboxamide

[0364]

[0365] A mixture of 2-(((R)-2-amino-3-methylbutyl)amino)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide (4 g, 12.48 mmol), TEA (0.5 mL) and CDI (3.04 g, 18.73 mmol) in THF (40 mL) was stirred under reflux for 1 hour. The reaction mixture was concentrated under reduced pressure, then diluted with water (50 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was analyzed by preparative MPLC (SiO 2 The product was purified by column chromatography, eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1) to give 2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide (3.5 g, yield: 80%). 1 H NMR (400 MHz, DMSO-d 6 )δppm 8.08(d,J=7.2Hz,2H),7.69(s,1H),7.37-7.33(m,1H),7.12(s,1H),7.05(s,1H),4.75(s,1H),3.87-3.83(m,2H),3. 63-3.55(m,2H),3.44-3.39(m,2H),3.14-3.12(m,1H),2.77(d,J=7.6Hz,3H),1.63-1.62(m,1H),0.89-0.83(m,6H).

[0366] Step 4: 5-amino-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-2,3-dihydro-1H- Indene-2-carboxamide

[0367]

[0368] 2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide (8.1 g, 25.58 mmol) was added to a flask in CH 3 Pd / C (1 g) was added to the solution in OH (80 mL). The reaction mixture was washed with H 2 Purge 3 times and 2 The mixture was hydrogenated at 50°C under a 50 psi atmosphere for 12 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The crude product was analyzed by preparative MPLC (SiO 2Column, eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1) to obtain 5-amino-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-2,3-dihydro-1H-indene-2-carboxamide (6.1 g, yield: 70%). MS (ESI, m / e) [M+H] + 317.3.

[0369] Step 5: ((1S)-1-cyclohexyl-2-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(methylamino tert-Butyl (2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)carbamate

[0370]

[0371] To a solution of 5-amino-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-2,3-dihydro-1H-indene-2-carboxamide (1.5 g, 4.74 mmol), TEA (719.59 mg, 7.11 mmol) and (S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetic acid (1.45 g, 5.69 mmol) in DCM (20 mL) at 0° C. was added HATU (2.16 g, 5.69 mmol). The mixture was stirred at 20° C. for 3 h. The reaction mixture was then filtered through H 2 O (50 mL) and extracted with DCM (50 mL × 3). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was analyzed by preparative MPLC (SiO 2 The product was purified by column chromatography, eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 1 / 1) to give tert-butyl ((1S)-1-cyclohexyl-2-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)carbamate (2.5 g, yield: 95%). 1 H NMR (400 MHz, DMSO-d 6 )δppm9.75(s,1H),7.52-7.45(m,2H),7.34-7.26(m,1H),7.16-7.08(m ,1H),6.82–6.75(m,2H),3.92-3.90(m,1H),3.56-3.48(m,2H),3.21-3. 18(m,2H),3.11-3.08(m,2H),2.90-2.88(m,1H),2.56(d,J=4.4Hz,3H) ,1.75-1.50(m,6H),1.42(s,9H),1.15-1.02(m,4H),0.74-0.65(m,6H).

[0372] Step 6: 5-((S)-2-amino-2-cyclohexylacetylamino)-2-((R)-4-isopropyl-2-oxoimidazolidine-1-yl)- 2,3-dihydro-1H-indene-2-carboxamide (IntA2)

[0373] A solution of tert-butyl ((1S)-1-cyclohexyl-2-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)carbamate (2.5 g, 4.5 mmol) in DCM (20 mL) and TFA (5 mL) was stirred at 20° C. for 3 h. After concentrating in vacuo to remove TFA, the reaction mixture was passed through saturated NaHCO 3 (50 mL) and extracted with DCM (100 mL×3). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was analyzed by preparative MPLC (SiO 2 The product was purified by column chromatography, eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1) to give 5-((S)-2-amino-2-cyclohexylacetylamino)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-2,3-dihydro-1H-indene-2-carboxamide (1270 mg, yield: 62%). 1 H NMR (400 MHz, DMSO-d 6 )δppm 10.25(s,1H),7.55-7.44(m,4H),7.37-7.31(m,1H),7.15(d,J=8.0Hz,1 H),6.77(d,J=11.2Hz,1H),3.60-3.48(m,3H),3.36-3.34(m,3H),3.22- 3.16(m,2H),2.84-2.82(m,1H),2.56(d,J=4.4Hz,3H),1.75-1.50(m,6H ),1.45(s,1H),1.15-1.02(m,5H),0.74-0.67(m,6H).MS(ESI,m / e)[M+H] + 456.3.

[0374] Int A3: 5-((S)-2-amino-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-(o-tolyl)-2,3-dihydro-1H-indene-2-carboxamide

[0375] Step 1: 5-amino-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid Methyl ester

[0376]

[0377] At room temperature, in N 2 To a solution of methyl 2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-5-nitro-2,3-dihydro-1H-indene-2-carboxylate (5.9 g, 16.9 mmol, prepared by a procedure analogous to 2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide described in Int A2) in MeOH (60 mL) was added Raney nickel (0.6 g, 1.69 mmol). The mixture was stirred at 4 ℃ for 2 h. 2 The mixture was hydrogenated at 60 °C for 1 hour under a 15 psi atmosphere. The reaction mixture was filtered through a pad of celite and washed with MeOH (50 mL). The filtrate was concentrated in vacuo to give methyl 5-amino-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylate (2.5 g, crude product), which was used directly in the next step. MS (ESI, m / e) [M+H] + 318.1.

[0378] Step 2: 5-((S)-2-(((Benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl Propyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0379]

[0380] To a solution of 5-amino-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (2.5 g), DIEA (3.05 g, 23.6 mmol) and (S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionic acid (2.39 g, 7.88 mmol) in DCM (25 mL) at 0°C was added HATU (3.0 g, 7.88 mmol). The mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water (30 mL) and then extracted with DCM (30 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1) to give 5-((S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (2.5 g, yield: 53%). MS (ESI, m / e) [M+H] + 603.3.

[0381] Step 3: 5-((S)-2-(((Benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl Propyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid

[0382]

[0383] In N 2 To a solution of methyl 5-((S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylate (2.5 g, 4.13 mmol) in THF (47 mL) was added H 2 O (10 mL), LiOH.H 2 O (654 mg, 8.26 mmol). The mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with HCl acid (30 mL, 0.5 M) under stirring and then extracted with EtOAc (35 mL×3). The combined organic phase was washed with brine (40 mL) and washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo to give 5-((S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid (1.0 g, yield: 50%). 1 H NMR (400 MHz, DMSO-d 6 )δppm 12.5(s,1H),9.84(s,1H),7.23-7.53(m,8H),7.13-7.11(m,1H),6.75(d,J=2.4Hz,1H),5.06(s,2H),4.29-4.44(m,1H),3.42-3.52(m,2H),3.36(s,2H),3.16-3.24(m,1H),3.04-3.13(m,1H),1.50-1.47(m,1H),0.70-0.92(m,9H),0.08-0.61(m,10H). MS experimental value: [M+H] + 589.4.

[0384] Step 4: ((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-( Benzyl (2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate

[0385]

[0386] To a solution of 5-((S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid (0.15 g, 254.80 umol) in DCM (5 mL) at 0°C were added o-toluidine (0.027 g, 0.255 mmol), DIEA (65.86 mg, 509.60 umol) and HATU (116.24 mg, 305.76 umol). The mixture was stirred at room temperature for 12 hours. The reaction mixture was washed with H 2 O (5 mL), and then extracted with DCM (5 mL x 3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was purified by preparative TLC (silica gel, eluent: petroleum ether / ethyl acetate (v / v) = 5:1, R f =0.1) to give benzyl ((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(o-tolylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate (0.105 g, yield: 61%).

[0387] Step 5: 5-((S)-2-amino-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl-2-oxoimidazole alkyl-1-yl)-N-(o-tolyl)-2,3-dihydro-1H-indene-2-carboxamide (IntA3)

[0388] At 20°C, in H 2 To a solution of benzyl ((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(o-tolylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate (0.105 g, 0.155 mmol) in MeOH (1 mL) and MeNH2.H2O (0.1 mL) was added Pd(OH)2 / C (0.1 g, 0.155 mmol). The mixture was stirred at 50°C under H 2 The reaction mixture was filtered and the filtrate was concentrated in vacuo. The crude product was purified by preparative TLC (silica gel, eluent: ethyl acetate / MeOH (v / v) = 10 / 1, R f =0.2) to obtain the title compound Int A3 (65 mg, yield: 77%). MS experimental value: [M+H] + 544.5.

[0389] Another key intermediate having a carboxamide group at position 2 of the 2,3-dihydro-1H-indene core fragment was synthesized according to similar methods / procedures known to those skilled in the art as intermediate Int A1 or Int A2 or Int A3; different materials for aldehydes and amino acids are also listed in the table.

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400] Protected amino acids or aldehydes are commercially available, known in the literature or can be synthesized as outlined in the illustrated preparations.

[0401] Int B1: 5-(5-amino-2-(1H-benzo[d]imidazol-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one

[0402] Step 1: 5-nitro-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2- Formic acid

[0403]

[0404] To a solution of N-methyl-5-nitro-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2-carboxamide (2.1 g, 6.1 mol, prepared by a procedure similar to 2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide as described in Int A2) in DCM (15 mL) was added TFA (5 mL) and stirred at room temperature for 4 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo to remove TFA and solvent. The residue was diluted with DCM (50 mL) and washed with saturated NaHCO3 (20 mL) and then washed with saturated NH4Cl (20 mL). The organic solution was washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo to give 5-nitro-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2-carboxylic acid (2 g, yield: 98%). MS experimental value: [M+H] + 332.4.

[0405] Step 2: N-(2-aminophenyl)-5-nitro-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2, 3-Dihydro-1H-indene-2-carboxamide

[0406]

[0407] To a solution of 5-nitro-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2-carboxylic acid (0.5 g, 1.51 mmol), benzene-1,2-diamine (0.26 g, 1.51 mmol) and TEA (0.3 g, 3 mmol) in DCM (10 mL) was added HATU (0.0.65 g, 1.7 mmol) at 0°C. The mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 The residue was dried, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 1 / 1) to give N-(2-aminophenyl)-5-nitro-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2-carboxamide (0.18 g, yield: 28%). MS experimental value: [M+H] + 422.4.

[0408] Step 3: 5-(2-(1H-benzo[d]imidazol-2-yl)-5-nitro-2,3-dihydro-1H-inden-2-yl)-5,7-dihydro- Spiro[2.5]octan-6-one

[0409]

[0410] A solution of N-(2-aminophenyl)-5-nitro-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-indene-2-carboxamide (0.18 g, 0.45 mmol) in AcOH (8 mL) was heated to 50 °C and stirred for 4 hours. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO4 Dry, filter and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 50 / 1 to 5 / 1) to give 5-(2-(1H-benzo[d]imidazol-2-yl)-5-nitro-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one (80 mg, yield: 44%). MS experimental value: [M+H] + 404.2.

[0411] Step 4: 5-(5-amino-2-(1H-benzo[d]imidazol-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-diazo Spiro[2.5]octan-6-one (IntB1)

[0412] In N 2 To a solution of 5-(2-(1H-benzo[d]imidazol-2-yl)-5-nitro-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one (80 mg, 0.09 mmol) in MeOH (10 mL) was added Raney nickel (11 mg) and NH 3·H 2 O (1 mL). The suspension was degassed under vacuum and washed with H 2 The mixture was heated at 50 °C under H 2 The mixture was stirred for 1 hour under atmospheric pressure. The reaction mixture was filtered and concentrated in vacuo to give 5-(5-amino-2-(1H-benzo[d]imidazol-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one (70 mg, yield: 54%). 1 H NMR(400MHz,DMSO-d6)δppm 11.89(s,1H),7.55-7.38(m,2H),7.07(s,2H),6.79(d,J=6.8Hz,1H),6.47-6.11(m,3H),4 .79(s,2H),4.06-3.82(m,2H),3.27-3.09(m,4H),2.86(d,J=7.2Hz,2H),0.49-0.27,4H). [M+H] + 374.2.

[0413] Int B2: 5-(5-amino-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one

[0414] Step 1: Ethyl 5-bromo-2-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-indene-2-carboxylate.

[0415]

[0416] To a solution of ethyl 2-amino-5-bromo-2,3-dihydro-1H-indene-2-carboxylate (4 g, 14.1 mmol) in DCM (60 mL) was added Boc 2 O (7.7 g, 35.3 mmol). The mixture was heated to reflux and stirred for 15 hours. The reaction mixture was cooled to room temperature and concentrated. The residue was purified by silica gel column chromatography (eluent: EtOAc / PE (v / v) = 1 / 5) to give ethyl 5-bromo-2-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-indene-2-carboxylate (4.8 g, yield: 91%). MS (ESI) m / e [M-56+1] + 328.1.

[0417] Step 2: 5-Bromo-2-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-indene-2-carboxylic acid.

[0418]

[0419] To a solution of ethyl 5-bromo-2-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-indene-2-carboxylate (3.45 g, 9.0 mmol) in THF (45 mL) was added NaOH solution (1.44 g in 15 mL H 2 4 ) dropwise with stirring at room temperature. 2 O). The resulting mixture was heated to 55 ° C and stirred for 16 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was diluted with water and the mixture was adjusted to pH about 5 with HCl acid (1N), and then extracted with EtOAc (50×3mL). The organic layer was washed with brine, dried and concentrated in vacuo. The crude product was stirred in EtOAc / PE (1:1) at room temperature for 10 minutes. The solid was collected by filtration and dried in vacuo to give 5-bromo-2-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-indene-2-carboxylic acid (3 g, yield: 93%). MS (ESI) m / e [M+23] + 378.1.

[0420] Step 3: tert-(5-bromo-2-(methoxy(methyl)carbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamic acid Butyl ester.

[0421]

[0422] To a solution of 5-bromo-2-((tert-butoxycarbonyl)amino)-2,3-dihydro-1H-indene-2-carboxylic acid (2.3 g, 6.5 mmol) in DCM (50 mL) was added N,O-dimethylhydroxylamine hydrochloride (698 mg, 7.1 mmol) and HATU (2.7 g, 7.1 mmol), DIPEA (3.3 g, 25.9 mmol) dropwise at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with EtOAc. The organic layer was washed with saturated NaHCO 3 The solution (aqueous solution) was washed with brine, dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: EtOAc / PE (v / v) = 1 / 2) to give tert-butyl (5-bromo-2-(methoxy(methyl)carbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate (2.3 g, yield: 88%). MS (ESI) m / e [M-56+1] + 343.2.

[0423] Step 4: tert-Butyl (2-acetyl-5-bromo-2,3-dihydro-1H-inden-2-yl)carbamate.

[0424]

[0425] Below -10°C, in N 2 To a solution of tert-butyl (5-bromo-2-(methoxy(methyl)carbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate (1.55 g, 3.9 mmol) in THF (25 mL) was added CH 3 MgCl (4 mL, 11.7 mmol). The resulting mixture was stirred at 0°C for 1 hour. The reaction mixture was poured into saturated NH 4 Cl aqueous solution (30mL) and extracted with EtOAc (30mL×3). The combined organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: EtOAc / PE (v / v) = 1 / 6) to give tert-butyl (2-acetyl-5-bromo-2,3-dihydro-1H-inden-2-yl)carbamate (1.3 g, yield: 94%). MS (ESI) m / e [M+23] + 376.1.

[0426] Step 5: (5-bromo-2-(1-((trimethylsilyl)oxy)vinyl)-2,3-dihydro-1H-inden-2-yl)amine tert-Butyl formate.

[0427]

[0428] Tert-butyl (2-acetyl-5-bromo-2,3-dihydro-1H-inden-2-yl)carbamate (1.1 g, 3.1 mmol) was dissolved in THF (15 mL) and stirred at N2 Cool to -70°C under N atmosphere. 2 To this solution, LDA (3.1 mL, 6.2 mmol) was added dropwise under stirring under atmosphere. After the resulting mixture was stirred for 30 minutes, TMSCl (680 mg, 6.2 mmol) was added at -70°C. After further stirring at -60°C for 1 hour, the reaction mixture was passed through NH 4 The mixture was quenched with Cl(aq) and then diluted with EtOAc. The organic layer was separated, washed with water and brine, dried and concentrated in vacuo to give the crude product (1.5 g), which was used directly in the next step.

[0429] Step 6: tert-Butyl (5-bromo-2-(2-bromoacetyl)-2,3-dihydro-1H-inden-2-yl)carbamate.

[0430]

[0431] To a solution of tert-butyl (5-bromo-2-(1-((trimethylsilyl)oxy)vinyl)-2,3-dihydro-1H-inden-2-yl)carbamate (1.5 g, crude material) in THF (20 mL) was added NBS (625 mg, 3.5 mmol) in portions at 0°C. The mixture was stirred at 0°C for 1 hour. The reaction mixture was purified by NaHCO 3 The (aqueous solution) was quenched and diluted with EtOAc (30 mL). The organic layer was separated, washed with water and brine, dried and concentrated. The residue was purified by silica gel column chromatography (eluent: EtOAc / PE (v / v) = 1 / 7) to give tert-butyl (5-bromo-2-(2-bromoacetyl)-2,3-dihydro-1H-inden-2-yl)carbamate (740 mg, two-step yield: 55%). MS (ESI) m / e [M+23] + 456.1.

[0432] Step 7: tert-(5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)carbamic acid Butyl ester.

[0433]

[0434] A solution of tert-butyl (5-bromo-2-(2-bromoacetyl)-2,3-dihydro-1H-inden-2-yl)carbamate (740 mg, 1.72 mmol) and pyridin-2-amine (162 mg, 1.72 mmol) in MeOH (10 mL) was heated to 80 °C under N 2Stir for 24 hours under atmosphere. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: EtOAc / PE (v / v) = 1 / 2) to give tert-butyl (5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)carbamate (250 mg, yield: 34%). MS (ESI) m / e [M+1] + 428.2.

[0435] Step 8: 5-Bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-amine.

[0436]

[0437] To a solution of tert-butyl (5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)carbamate (250 mg, 0.59 mmol) in DCM (16 mL) was added HCl (4N in dioxane, 4 mL) dropwise at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo to give 5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-amine (180 mg, crude) as the HCl salt. MS (ESI) m / e [M+1] + 328.1.

[0438] Step 9: ((1-(((5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)amino tert-butyl (1-(2-(4-(6-methyl)cyclopropyl)-1-(2-methyl)carbamate.

[0439]

[0440] A mixture of 5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-amine (180 mg, 0.55 mmol) and tert-butyl ((1-formylcyclopropyl)methyl)carbamate (154 mg, 0.77 mmol) in DCM (10 mL) was stirred at room temperature for 1 hour. To this mixture was then added NaBH in portions at 0°C. 3 CN (351 mg, 1.66 mmol). The resulting mixture was stirred at room temperature overnight. The reaction mixture was washed with NaHCO 3(aqueous solution) was quenched and extracted with EtOAc (30mL). The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by preparative TLC (eluent: DCM / EtOAc (v / v) = 1 / 1) to give ((1-(((5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-indene-2-yl)amino)methyl)cyclopropyl)-methyl)carbamic acid tert-butyl ester (200mg, two-step yield: 67%). MS (ESI) m / e [M+1] + 511.3.

[0441] Step 10: N-((1-(aminomethyl)cyclopropyl)methyl)-5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)- 2,3-Dihydro-1H-inden-2-amine.

[0442]

[0443] To a solution of tert-butyl ((1-(((5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)methyl)cyclopropyl)-methyl)carbamate (200 mg, 0.39 mmol) in DCM (9 mL) was added HCl (4N in dioxane, 3 mL) dropwise at 0°C. The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was then concentrated and N-((1-(aminomethyl)cyclopropyl)methyl)-5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-amine HCl salt (200 mg, crude) was obtained and used directly in the next step. MS (ESI) m / e[M+1] + 411.2.

[0444] Step 11: 5-(5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-dihydro- Azaspiro[2.5]octan-6-one .

[0445]

[0446] To a solution of N-((1-(aminomethyl)cyclopropyl)methyl)-5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-amine (200 mg) and TEA (1 mL) in THF (10 mL) was added CDI (198 mg, 1.22 mmol). The mixture was heated to 60 °C and stirred for 1 hour. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with water and brine, dried and concentrated in vacuo. The crude product was purified by preparative TLC (eluent: DCM / MeOH (v / v) = 15 / 1) to give 5-(5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one (100 mg, yield for two steps: 58%). MS (ESI) m / e [M+1] + 437.2.

[0447] Step 12: 5-(5-((diphenylmethylene)amino)-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro- 1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one .

[0448]

[0449] To a solution of 5-(5-bromo-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one (100 mg, 0.23 mmol) in dioxane (15 mL) were added diphenylformimide (62.3 mg, 0.34 mmol), Pd 2 dba 3 (21mg, 0.02mmol), Xantphos (27mg, 0.04mmol) and Cs 2 CO 3 (150 mg, 0.46 mmol). The mixture was washed with N 2 Degas, heat to 100 °C, then 2 Stir for 6 hours under atmosphere. The reaction mixture was cooled to room temperature and diluted with DCM / MeOH (v / v=15 / 1). After filtering out the solid, the filtrate was concentrated and purified by preparative TLC (eluent: DCM / MeOH (v / v)=20 / 1) to give 5-(5-((diphenylmethylene)amino)-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-indene-2-yl)-5,7-diazaspiro[2.5]octan-6-one (58 mg, yield: 47%). MS (ESI) m / e[M+1] + 538.4.

[0450] Step 13: 5-(5-amino-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7- Diazaspiro[2.5]octan-6-one (IntB2)

[0451] To a solution of 5-(5-((diphenylmethylene)amino)-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-inden-2-yl)-5,7-diazaspiro[2.5]octan-6-one (58 mg, 0.11 mmol) in THF (5 mL) was added HCl (3 N, 1 mL) at room temperature and stirred for 30 min. The resulting reaction mixture was poured into saturated NaHCO 3 The product was added into an aqueous solution and then extracted with EA (30×3 mL). The combined organic layers were washed with brine, dried, filtered and concentrated in vacuo. The residue was purified by preparative TLC (eluent: DCM / MeOH (v / v) = 10 / 1) to give 5-(5-amino-2-(imidazo[1,2-a]pyridin-2-yl)-2,3-dihydro-1H-indene-2-yl)-5,7-diazaspiro[2.5]octan-6-one (22 mg, yield: 55%). MS (ESI) m / e[M+1] + 374.3.

[0452] Int C1: (4S)-1-(1-(6-amino-2,3-dihydrobenzofuran-2-yl)ethyl)-4-(trifluoromethyl)imidazolidin-2-one

[0453] Step 1: 1-(6-Nitrobenzofuran-2-yl)ethan-1-one

[0454]

[0455] 2-Hydroxy-4-nitrobenzaldehyde (2 g, 12 mmol) and 1-chloropropan-2-one (1.1 g, 12 mmol) were reacted in CH 3 K was added to the solution in CN (20 mL) 2 CO 3 (3.3 g, 24 mmol). The mixture was stirred at room temperature for 4 hours. The reaction mixture was poured into water (40 mL) and then extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The residue was purified by silica gel column chromatography (eluent: PE / EA (v / v) = 100 / 1 to 10 / 1) to give 1-(6-nitrobenzofuran-2-yl)ethanone (0.61 g, yield: 25%). MS (ESI) m / e [M+1] + 206.2.

[0456] Step 2: (S)-1,1,1-trifluoro-3-((1-(6-nitrobenzofuran-2-yl)ethylidene)amino)propan-2-amine

[0457]

[0458] To a solution of 1-(6-nitrobenzofuran-2-yl)ethanone (0.4 g, 1.9 mmol) and (S)-3,3,3-trifluoropropane-1,2-diamine hydrochloride (0.164 g, 2.9 mmol) in DCM (10 mL) was added TEA (0.101 g, 19.5 mmol) and 4AMS (1 g). The mixture was stirred at 45 ° C for 3 hours. After filtering the reaction mixture, the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: PE / EA (v / v) = 100 / 1 to 0 / 1) to give (S)-3,3,3-trifluoro-N1-(1-(6-nitrobenzofuran-2-yl)ethylidene)propane-1,2-diamine (0.5 g, yield: 81%). MS (ESI) m / e [M+1] + 316.1.

[0459] Step 3: (2S)-3,3,3-trifluoro-N1-(1-(6-nitrobenzofuran-2-yl)ethyl)propane-1,2-diamine

[0460]

[0461] To a solution of (S)-3,3,3-trifluoro-N1-(1-(6-nitrobenzofuran-2-yl)ethylidene)propane-1,2-diamine (0.5 g, 1.6 mmol) in MeOH (10 mL) was added NaBH 3 CN (1 g, 16 mmol). The mixture was stirred at 70°C for 12 hours. The mixture was poured into water (20 mL) and then extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The residue is purified. The crude product is purified by silica gel column chromatography (eluent: DCM / CH 3 OH (v / v) = 100 / 1 to 10 / 1) to give (2S)-3,3,3-trifluoro-N1-(1-(6-nitrobenzofuran-2-yl)ethyl)propane-1,2-diamine (0.32 g, yield: 64%). MS (ESI) m / e [M+1] + 318.2.

[0462] Step 4: (4S)-1-(1-(6-nitrobenzofuran-2-yl)ethyl)-4-(trifluoromethyl)imidazolidin-2-one

[0463]

[0464] To a solution of (2S)-3,3,3-trifluoro-N1-(1-(6-nitrobenzofuran-2-yl)ethyl)propane-1,2-diamine (1.2 g, 3.8 mmol) in THF (15 mL) was added CDI (0.92 g, 5.7 mmol) and TEA (0.5 mL) at 20 °C. The mixture was stirred at 60 °C for 6 hours. The reaction mixture was diluted with EtOAc (30 mL) and then washed with brine. The organic layer was purified by anhydrous Na 2 SO 4 The residue was dried, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: PE / EAE (v / v) = 100 / 1 to 10 / 1) to give (4S)-1-(1-(6-nitrobenzofuran-2-yl)ethyl)-4-(trifluoromethyl)imidazolidin-2-one (0.34 g, yield: 26%). MS (ESI) m / e [M+1] + 344.3.

[0465] Step 5: (4S)-1-(1-(6-amino-2,3-dihydrobenzofuran-2-yl)ethyl)-4-(trifluoromethyl)imidazole Alkane-2-one (Int C1)

[0466]

[0467] To a solution of (4S)-1-(1-(6-nitrobenzofuran-2-yl)ethyl)-4-(trifluoromethyl)imidazolidin-2-one (0.32 g, 0.932 mmol) in i-PrOH (5 mL) was added Pd / C (0.1 g, 0.932 mmol) at room temperature. The mixture was heated to 50° C. and stirred under H 2 The reaction mixture was hydrogenated under an atmosphere of (15 psi) for 2 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo to obtain (4S)-1-(1-(6-amino-2,3-dihydrobenzofuran-2-yl)ethyl)-4-(trifluoromethyl)imidazolidin-2-one (282 mg). 1 H NMR (400 MHz, CDCl 3 )δppm 7.02-6.84(m,1H),6.79-6.12(m,2H),5.10-4.92(m,1H),4.91-4.72(m,1H),4.20-4.09(m,1H), 4.06-3.90(m,1H),3.83-3.66(m,1H),3.65-3.49(m,2H),3.48-2.80(m,1H),1.58-1.12(m,3H). MS(ESI,m / e)[M+H] + 316.1.

[0468] Example 32: N-((1S)-cyclohexyl(6-((R)-4-ethyl-2-oxoimidazolidin-1-yl)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)methyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide

[0469]

[0470] Step 1: 2-amino-N-methyl-5,6-dinitro-2,3-dihydro-1H-indene-2-carboxamide

[0471]

[0472] At 0°C, H 2 SO 4 (100 mL) and HNO 3 2-Amino-N-methyl-2,3-dihydro-1H-indene-2-carboxamide (19 g, 100 mmol, dissolved in 10 mL HOAc) was slowly added in portions to a mixture of 4% ethanol (25 mL). After the addition, the mixture was stirred at room temperature for 4 hours. The reaction mixture was carefully poured into saturated NaHCO at 0-10 °C. 3 (aqueous solution, 500 mL), then extracted with DCM (500 mL). The organic layer was separated and purified by silica gel column chromatography (eluent: DCM to DCM / MeOH (v / v) = 20 / 1) to give the title compound (16.81 g, yield: 60.0%).

[0473] Step 2: tert-Butyl (2-(methylcarbamoyl)-5,6-dinitro-2,3-dihydro-1H-inden-2-yl)carbamate ester

[0474]

[0475] 2-Amino-N-methyl-5,6-dinitro-2,3-dihydro-1H-indene-2-carboxamide (16.81 g, 60 mmol) and Boc 2 A mixture of 1,2-dihydro-1,4-dihydro-2-nitropropene (2,6-dihydro-1,4-dihydro-2,4 ...1,4-dihydro-2,4-dihydro-1,4-dihydro-2,4-dihydro-1,4-dihydro-1,4-dihydro-2,4-dihydro-1,4-dihydro-2,4-dihydro-1,4-dihydro-1,4-dihydro-2,4-dihydro-1,4-dihydro 2 SO 4 Dry and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title product (19.76 g, yield: 86.7%). MS (ESI, m / e) [M+1] + 381.3.

[0476] Step 3: tert-Butyl (5,6-diamino-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate ester

[0477]

[0478] A mixture of tert-butyl (2-(methylcarbamoyl)-5,6-dinitro-2,3-dihydro-1H-inden-2-yl)carbamate (19.76 g, 52 mmol) and Pd / C (1.5 g) in MeOH (500 mL) was treated with H 2 The balloon is bubbled and 2 Stir overnight under atmosphere. The reaction mixture was filtered and the filtrate was concentrated in vacuo, and then purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title compound (14.7 g, yield: 88.46%). MS (ESI, m / e) [M+1] + 321.3.

[0479] Step 4: ((1S)-2-((6-amino-2-((tert-butoxycarbonyl)amino)-2-(methylcarbamoyl)-2,3- (dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamic acid benzyl ester

[0480]

[0481] A mixture of (S)-2-(((benzyloxy)carbonyl)amino)-2-cyclohexylacetic acid (13.4 g, 46 mmol), tert-butyl (5,6-diamino-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-2-yl)carbamate (14.70 g, 46 mmol), HATU (19 g, 50 mmol) and TEA (10 g, 100 mmol) in DCM (500 mL) was stirred at room temperature overnight. The reaction mixture was washed with NaHCO 3 (aqueous solution, 500 mL). The organic layer was separated, washed with brine (500 mL), and 2 SO 4 Dry and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title compound (9.0 g, yield: 32.95%). MS (ESI, m / e) [M+1] + 594.3.

[0482] Step 5: ((1S)-(6-((tert-Butyloxycarbonyl)amino)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindene Benzyl (5,6-d)imidazol-2-yl)(cyclohexyl)methyl)carbamate

[0483]

[0484] A mixture of benzyl ((1S)-2-((6-amino-2-((tert-butoxycarbonyl)amino)-2-(methylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)carbamate (9.0 g) and AcOH (50 mL) was heated to 100° C. and stirred overnight. The reaction mixture was concentrated in vacuo and the residue was washed with NaHCO 3 (aqueous solution, 250 mL) and extracted with DCM (250 mL), washed with brine (500 mL), and purified by Na 2 SO 4 Dry and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title compound (1.63 g, yield: 39.36%). MS (ESI, m / e) [M+1] + 576.3.

[0485] Step 6: ((1S)-(6-amino-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazole-2-yl)- Benzyl (cyclohexyl)methyl)carbamate

[0486]

[0487] To a solution of benzyl ((1S)-(6-((tert-butoxycarbonyl)amino)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate (5.0 g, 8.69 mmol) in DCM (100 mL) was added HCl acid (4 M in dioxane, 100 mL). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was washed with NaHCO 3 (aqueous solution, 250 mL) and extracted with DCM (250 mL). The organic layer was washed with brine (200 mL) and purified by Na 2 SO 4 Dry and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title compound (1.63 g, yield: 39.36%). MS (ESI, m / e) [M+1] + 476.2.

[0488] Step 7: ((1S)-(6-(((R)-2-((tert-butoxycarbonyl)amino)butyl)amino)-6-(methylcarbamoyl) Benzyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate

[0489]

[0490] Benzyl ((1S)-(6-amino-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate (300 mg, 0.63 mmol), (R)-tert-butyl (3-methyl-1-oxobutan-2-yl)carbamate (252 mg, 1.26 mmol) and NaBH(OAc) were added. 3 A mixture of (267 mg, 1.26 mmol) in DCM (50 mL) was stirred at room temperature for 2 h. The reaction mixture was washed with NaHCO 3 (aqueous solution, 100 mL) and extracted with DCM (50 mL). The organic layer was washed with Na 2 SO 4 The residue was dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1). Benzyl ((1S)-(6-(((R)-2-((tert-butoxycarbonyl)amino)butyl)amino)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate (310 mg, yield: 71.4%) was obtained. MS (ESI, m / e) [M+1] + 647.4.

[0491] Step 8: ((1S)-(6-(((R)-2-aminobutyl)amino)-6-(methylcarbamoyl)-1,5,6,7-tetrahydro Benzyl indeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate

[0492]

[0493] A mixture of benzyl ((1S)-(6-(((R)-2-((tert-butoxycarbonyl)amino)butyl)amino)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate (310 mg, 0.45 mmol) and TFA (2 mL) in DCM (5 mL) was stirred for 2 h. The mixture was concentrated in vacuo to give benzyl ((1S)-(6-(((R)-2-aminobutyl)amino)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate (236 mg, crude material) which was used directly in the next step. MS (ESI, m / e) [M+1] + 547.3.

[0494] Step 9: ((1S)-cyclohexyl(6-((R)-4-ethyl-2-oxoimidazolidin-1-yl)-6-(methylcarbamoyl) Benzyl (1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)methyl)carbamate

[0495]

[0496] A mixture of benzyl ((1S)-(6-(((R)-2-aminobutyl)amino)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)(cyclohexyl)methyl)carbamate (236 mg, 0.44 mmol), TEA (0.5 mL) and CDI (142 mg, 0.88 mmol) in THF (20 mL) was heated to 60 ° C and stirred for 2 hours. The reaction mixture was quenched with brine (50 mL) and extracted with EA (50×2 mL). The combined layers were purified by Na 2 SO 4 The mixture was dried and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1). Benzyl ((1S)-cyclohexyl (6-((R)-4-ethyl-2-oxoimidazolidin-1-yl)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno [5,6-d] imidazole-2-yl) methyl) carbamate (236 mg, yield: 93.18%) was obtained. MS (ESI, m / e) [M+1] + 573.3.

[0497] Step 10: 2-((S)-amino(cyclohexyl)methyl)-6-((R)-4-ethyl-2-oxoimidazolidin-1-yl)-N-methyl 1,5,6,7-tetrahydroindeno[5,6-d]imidazole-6-carboxamide

[0498]

[0499] To a mixture of benzyl ((1S)-cyclohexyl(6-((R)-4-ethyl-2-oxoimidazolidin-1-yl)-6-(methylcarbamoyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)methyl)carbamate (236 mg, 0.41 mmol) and Pd / C (20 mg) in MeOH (50 mL) was added H 2 The balloon is bubbled and 2 Stir overnight under atmosphere for deprotection. The reaction mixture was then filtered and the filtrate was concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to give the title amine compound (142 mg, yield: 55.66%). MS (ESI, m / e) [M+1] + 439.3.

[0500] Step 11: N-((1S)-cyclohexyl(6-((R)-4-ethyl-2-oxoimidazolidin-1-yl)-6-(methylamino)methoxy (acyl)-1,5,6,7-tetrahydroindeno[5,6-d]imidazol-2-yl)methyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide (real Example 32)

[0501] To a solution of 2-((S)-amino(cyclohexyl)methyl)-6-((R)-4-ethyl-2-oxoimidazolidin-1-yl)-N-methyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazole-6-carboxamide (22 mg, 0.05 mmol) in DCM (10 mL) was added 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (7 mg, 0.05 mmol), HATU (19 mg, 0.05 mmol) and TEA (10 mg, 0.1 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was washed with NaHCO 3 The organic layer was quenched with aqueous solution (50 mL) and diluted with DCM (20 mL). 2 SO 4 Dry, filter and concentrate in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1 to 20 / 1) to obtain the title compound (13 mg, yield: 47.4%). 1 H NMR (400 MHz, DMSO-d 6 )δppm:12.20(br,1H),9.42(d,J=8.8Hz,1H),7.55-7.25(m,3H),6.69(s,1H),5.05(t,J=8.4Hz,1H),3.65-3.40(m,4H),3.32-3.23 (m,2H),2.93-2.87(m,1H),2.58(d,J=4.4Hz,3H),2.10-1.55(m,5H),1.42-1.27(m,3H),1.21-0.95(m,5H),0.71(t,J=7.2Hz,3H). MS(ESI,m / e)[M+1] + 549.4.

[0502] Example 145: N-((1S)-1-cyclohexyl-2-((6-(methylcarbamoyl)-6-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide

[0503]

[0504] Step 1: 9,12-dioxa-1,3-diazabispiro[4.2.4 8 .2 5 ]Tetradecane-2,4-dione

[0505]

[0506] 1,4-dioxaspiro[4.5]decan-8-one (9.55 g, 61.2 mmol), NaCN (3 g, 61.2 mmol) and (NH4 ) 2 CO 3 (23.5 g, 244.8 mmol) in H 2 A mixture of 2-nitropropene (100 mL) and EtOH (5 mL) was stirred at 60 °C overnight. The reaction mixture was cooled to room temperature and allowed to stand for 1 day. The precipitate was filtered and the filter cake was dried in air to give 9,12-dioxa-1,3-diazabispiro[4.2.4 8 .2 5 ]Tetradecane-2,4-dione (7.38 g, crude material). 1 H NMR (400 MHz, DMSO-d 6 )δppm:10.59(s,1H),8.44(s,1H),3.87(s,4H),1.95-1.78(m,2H),1.73-1.69(m,4H),1.59-1.56(m,2H).

[0507] Step 2: 8-Amino-1,4-dioxaspiro[4.5]decane-8-carboxylic acid

[0508]

[0509] 9,12-dioxa-1,3-diazabispiro[4.2.4 8 .2 5 ] A solution of tetradecane-2,4-dione (2 g) in NaOH solution (6N, 15 mL) was stirred in a sealed tube at 140 ° C for 3 hours. The reaction mixture was cooled to room temperature and acidified to pH = 4 with 6N HCl acid. After the mixture was concentrated in vacuo to remove the solvent, the residue was dissolved with DCM / MeOH=10 / 1 (80 mL) and stirred for 10 minutes. The mixture was filtered and the filtrate was concentrated to give 8-amino-1,4-dioxaspiro[4.5]decane-8-carboxylic acid (1.13 g, crude material). MS (ESI) m / e[M+1] + 202.1

[0510] Step 3: 8-(((Benzyloxy)carbonyl)amino)-1,4-dioxaspiro[4.5]decane-8-carboxylic acid

[0511]

[0512] 8-Amino-1,4-dioxaspiro[4.5]decane-8-carboxylic acid (1.13 g), CbzCl (966 mg) and Et 3 N (1.15 g, 3.06 mmol) in THF (30 mL) and H 2The mixture in 4% paraformaldehyde (2% paraformaldehyde) (2% paraformaldehyde) (2% paraformaldehyde) (3% paraformaldehyde) was stirred at room temperature for 3 hours. The reaction mixture was diluted with MTBE (30 mL) and stirred for 10 minutes. The aqueous phase was collected and concentrated in vacuo. The resulting solid was dried in air to give 8-(((benzyloxy)carbonyl)amino)-1,4-dioxaspiro[4.5]decane-8-carboxylic acid (1.86 g, crude material). MS (ESI) m / e[M+1] + 337.1.

[0513] Step 4: Benzyl (8-(methylcarbamoyl)-1,4-dioxaspiro[4.5]decan-8-yl)carbamate

[0514]

[0515] 8-(((Benzyloxy)carbonyl)amino)-1,4-dioxaspiro[4.5]decane-8-carboxylic acid (1.86 g), methylamine hydrochloride (385 mg, 5.7 mmol), HATU (2.17 g, 5.7 mmol) and Et 3 A mixture of N (1.15 g, 11.4 mmol) in DCM (60 mL) was stirred at room temperature overnight. The reaction mixture was concentrated, and the residue was then purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1). (8-(methylcarbamoyl)-1,4-dioxaspiro[4.5]dec-8-yl)benzylcarbamate (1.77 g) was obtained. MS (ESI) m / e[M+1] + 349.2.

[0516] Step 5: Benzyl (1-(methylcarbamoyl)-4-oxocyclohexyl)carbamate

[0517]

[0518] A solution of benzyl (8-(methylcarbamoyl)-1,4-dioxaspiro[4.5]decane-8-yl)carbamate (1.77 g, 5.7 mmol) in TFA (10 mL) was stirred at room temperature for 3 hours. The reaction mixture was concentrated to remove TFA. The residue was washed with NaHCO 3 The aqueous solution was neutralized and then extracted with DCM (50 mL×3). The organic layer was washed with brine and washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo to obtain benzyl (1-(methylcarbamoyl)-4-oxocyclohexyl)carbamate (615 mg, crude material). MS (ESI) m / e [M+1] + 305.1

[0519] Step 6: 2-amino-6-(((benzyloxy)carbonyl)amino)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzene tert-Butyl thiophene-3-carboxylate

[0520]

[0521] A mixture of (1-(methylcarbamoyl)-4-oxocyclohexyl)benzylcarbamate (615mg, 2.02mmol), tert-butyl 2-cyanoacetate (500mg, 2.02mmol), sulfur (65mg, 2.02mmol) and morpholine (176mg, 2.02mmol) in EtOH (25mL) was stirred overnight at 80°C. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by preparative TLC (eluent: EA / PE (v / v) = 1 / 1). 2-amino-6-(((benzyloxy)carbonyl)amino)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid tert-butyl ester (287mg) was obtained. MS (ESI) m / e[M+1] + 460.3.

[0522] Step 7: (2-amino-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)amino Benzyl ester

[0523]

[0524] To a solution of tert-butyl 2-amino-6-(((benzyloxy)carbonyl)amino)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (287 mg, 0.625 mmol) in THF (30 mL) was added HCl acid (6N, 10 mL). The mixture was stirred at 60 °C for 4 h. After cooling to room temperature, the reaction mixture was washed with NaHCO 3 The aqueous solution was neutralized and then extracted with DCM (50 mL×3). The organic layer was washed with brine and washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The residue was purified by preparative TLC (eluent: MeOH / DCM (v / v) = 1 / 10) to give benzyl (2-amino-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)carbamate (237 mg). MS (ESI) m / e [M+1] + 360.2.

[0525] Step 8: (2-((S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetylamino)-6-(methylamino) Benzyl (4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)carbamate

[0526]

[0527] To a solution of benzyl (2-amino-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)carbamate (237 mg, 0.625 mmol) in DCM (15 mL) was added (S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetic acid (161 mg, 0.625 mmol), HATU (238 mg, 0.625 mmol) and Et 3 N (189 mg, 1.875 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was purified by preparative TLC (MeOH / DCM=1 / 10). Benzyl (2-((S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetylamino)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-6-yl)carbamate (223 mg) was obtained. MS (ESI) m / e[M+1] + 599.3.

[0528] Step 9: (2-((S)-2-amino-2-cyclohexylacetylamino)-6-(methylcarbamoyl)-4,5,6,7-tetrakis Benzyl (6-(2-hydrobenzo[b]thiophene)carbamate

[0529]

[0530] A solution of benzyl (2-((S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetamido)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)carbamate (223 mg, 0.372 mmol) in TFA (5 mL) was stirred at room temperature for 1 hour. The reaction was concentrated in vacuo to give the crude title compound (300 mg). MS (ESI) m / e [M+1] + 499.4.

[0531] Step 10: (2-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-6-(methyl Benzyl (4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)carbamoyl)carbamate

[0532]

[0533] To a solution of benzyl (2-((S)-2-amino-2-cyclohexylacetamido)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)carbamate (300 mg) in DCM (15 mL) was added 1-methyl-1H-pyrazole-5-carboxylic acid (47 mg, 0.372 mmol), HATU (141 mg, 0.372 mmol) and Et 3N (190 mg, 1.86 mmol). The mixture was stirred at room temperature for 48 hours. The reaction mixture was concentrated in vacuo. The residue was purified by preparative TLC (eluent: MeOH / DCM (v / v) = 1 / 10) to give (2-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-6-yl)carbamic acid benzyl ester (90 mg). MS (ESI) m / e [M+1] + 607.4.

[0534] Step 11: N-((1S)-2-((6-amino-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophene- 2-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide

[0535]

[0536] To a solution of benzyl (2-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)carbamate (80 mg, 0.13 mmol) in DCM (10 mL) was added TMSI (1 mL, 1 mol / L). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was washed with NaHCO 3 The aqueous solution was neutralized and extracted with DCM (50 mL x 3). The organic layer was washed with brine and washed with anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. Obtain N-((1S)-2-((6-amino-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide (63 mg, crude material). MS (ESI) m / e [M+1] + 473.2.

[0537] Step 12: ((1-(((2-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)- 6-(Methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)amino)methyl)cyclopropyl)methyl)amino Tert-butyl ester

[0538]

[0539] N-((1S)-2-((6-amino-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide (30 mg, 0.063 mmol), tert-butyl ((1-formylcyclopropyl)methyl)carbamate (13 mg, 0.063 mmol) and NaBH(OAc) were added. 3A mixture of (14 mg, 0.063 mmol) in DCM (10 mL) was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was purified by preparative TLC (eluent: MeOH / DCM (v / v) = 1 / 15) to give the desired product (10 mg). MS (ESI) m / e [M+1] + 656.5.

[0540] Step 13: N-((1S)-2-((6-(((1-(aminomethyl)cyclopropyl)methyl)amino)-6-(methylcarbamoyl) 1-Methyl-1H-pyrazole-5-yl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino)-1-cyclohexyl-2-oxoethyl) Formamide

[0541]

[0542] A mixture of tert-butyl ((1-(((2-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thiophen-6-yl)amino)methyl)cyclopropyl)methyl)carbamate (10 mg) in TFA (2 mL) was stirred at room temperature for 30 minutes. The reaction was concentrated to give the desired product (10 mg) as a white solid. MS (ESI) m / e [M+1] + 556.4.

[0543] Step 14: N-((1S)-1-cyclohexyl-2-((6-(methylcarbamoyl)-6-(6-oxo-5,7-diazaspiro [2.5]oct-5-yl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole- 5-Formamide (Example 145)

[0544] To N-((1S)-2-((6-(((1-(aminomethyl)cyclopropyl)methyl)amino)-6-(methylcarbamoyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide (10 mg) and Et 3 To a solution of N (30 mg) in DMF (2 mL) was added CDI (3 mg). The mixture was stirred at 60 °C for 2 hours. The reaction mixture was concentrated in vacuo and the residue was purified by preparative TLC (eluent: MeOH / DCM (v / v) = 1 / 15). The title compound Example 145 (2 mg) was obtained. MS (ESI) m / e [M+1] + 582.2.

[0545] Example 170: N-((1S)-1-cyclohexyl-2-((2-isopropyl-2-(6-oxo-5,7-diazaspiro[2.5]octan-5-yl)-2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide

[0546]

[0547] Step 1: 6-bromo-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0548]

[0549] In N 2 Under protection, sodium hydride (8g oil containing 60% suspension, 200mmol) was added in batches to a solution of 6-bromo-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (27g) in anhydrous DMF (250ml) within 20 minutes. The mixture was stirred for 45 minutes. 2-iodopropane (34g, 200mmol) was added dropwise within 15 minutes, and the mixture was then stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was distributed between EA (150mL) and HCl acid (2N, 50mL). The organic layer was separated, dried and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluent: PE / EA (v / v) = 10 / 1). 6-bromo-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (10g, yield: 33%) was obtained. MS (ESI, m / e) [M+1] + 311.0 / 313.0.

[0550] Step 2: 6-((diphenylmethylene)amino)-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0551]

[0552] 6-bromo-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (3.11 g, 10 mmol), diphenylformimine (2.7 g, 15 mmol), BINAP (1.87 g, 0.3 mmol), Pd 2 (dba) 3 (1.4 g, 0.15 mmol) and Cs 2 CO 3 A mixture of (10 g, 30 mmol) in toluene (50 ml) was stirred with N 2 Degas. The mixture was heated to 100 °C and heated under N 2 The reaction mixture was cooled to room temperature and heated with H 2 O, and washed with brine. The organic layer was purified by MgSO 4 Dry, filter and concentrate in vacuo. The residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 10 / 1). 6-((diphenylmethylene)amino)-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (2.2 g, yield: 53.5%) was obtained. MS (ESI, m / e) [M+1]+ 412.1

[0553] Step 3: 6-amino-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0554]

[0555] 6-((Diphenylmethylene)amino)-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (2.2 g) was dissolved in HCl acid (1 N, 15 mL) and stirred for 1 hour. The reaction mixture was washed with NaHCO 3 The mixture was basified to pH = 8-9 and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with H 2 O, washed with brine, and MgSO 4 Dry, filter and concentrate in vacuo. The residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 1 / 1). 6-amino-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (1 g, yield: 76.9%) was obtained. MS (ESI, m / e) [M+1] + 248.1.

[0556] Step 4: 6-amino-1-hydroxy-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0557]

[0558] To a solution of methyl 6-amino-2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (1 g, 4 mmol) in MeOH (50 mL) was added NaBH in portions at 0 °C. 4 (154 mg, 12 mmol). The reaction mixture was stirred for 1 hour and then concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed with MgSO 4 Dry and concentrate in vacuo to obtain methyl 6-amino-1-hydroxy-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylate (1 g, crude material). MS (ESI, m / e) [M+1] + 250.1.

[0559] Step 5: 5-amino-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0560]

[0561] Triethylsilane (2 mL) was added to a solution of 6-amino-1-hydroxy-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (249 mg, 1 mmol) in TFA (10 mL). The mixture was stirred at room temperature for 1 hour. After the reaction mixture was concentrated to remove TFA, the residue was dissolved in DCM (25 mL) and saturated with NaHCO 3 The organic layer was washed with MgSO 4 Dry and concentrate in vacuo to obtain 5-amino-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (240 mg, crude material). MS (ESI, m / e) [M+1] + 234.1.

[0562] Step 6: 5-((S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetylamino)-2-isopropyl-2,3-dihydro- Hydrogen-1H-indene-2-carboxylic acid methyl ester

[0563]

[0564] To a solution of 5-amino-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (466 mg, 2 mmol) in DCM (25 mL) was added (S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetic acid (819 mg, 3 mmol), HATU (1.35 g, 3.6 mmol) and TEA (1 mL). The mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to remove the solvent and the residue was purified by preparative TLC (eluent: DCM / MeOH (v / v) = 15:1). 5-((S)-2-((tert-butoxycarbonyl)amino)-2-cyclohexylacetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (623 mg, yield: 56%) was obtained. MS (ESI, m / e) [M+1] + 473.3.

[0565] Step 7: 5-((S)-2-amino-2-cyclohexylacetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid Methyl ester

[0566]

[0567] 5-((S)-2-((tert-Butoxycarbonyl)amino)-2-cyclohexylacetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (623 mg, 1.32 mmol) was dissolved in HCl solution (10 mL, 2M in dioxane) and stirred at room temperature for 1 hour. After the reaction mixture was concentrated in vacuo to remove the solvent, 5-((S)-2-amino-2-cyclohexylacetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester salt (491 mg, crude material) of HCl was obtained. MS (ESI, m / e) [M+1] + 373.1.

[0568] Step 8: 5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl Methyl 2,3-dihydro-1H-indene-2-carboxylate

[0569]

[0570] To a solution of 5-((S)-2-amino-2-cyclohexylacetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (491 mg, crude material) and TEA (1.0 mL) in DCM (25 mL) was added 1-methyl-1H-pyrazole-5-carboxylic acid (200 mg, 1.58 mmol) and HATU (752 mg, 1.98 mmol). The mixture was stirred at room temperature for 2 hours. The reaction mixture was washed with NaHCO 3 The organic layer was quenched with aqueous solution (50 mL) and diluted with DCM (20 mL). 2 SO 4 Dry and concentrate in vacuo. The residue was purified by preparative TLC (eluent: DCM / MeOH (v / v) = 15:1). 5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (200 mg, yield: 32%) was obtained. MS (ESI, m / e) [M+1] + 481.1.

[0571] Step 9: 5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl 2,3-Dihydro-1H-indene-2-carboxylic acid

[0572]

[0573] To a solution of 5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (200 mg, 0.42 mmol) in methanol (5 mL) was added aqueous NaOH (2 mL, 1.0 N). The mixture was stirred at room temperature overnight. The reaction mixture was acidified to pH = 5-6 with dilute HCl acid and extracted with EtOAc (15 mL×3). The organic layer was washed with H 2 O, washed with brine, and MgSO 4 Dry, filter and concentrate in vacuo to obtain 5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid (100 mg, crude material). MS (ESI, m / e) [M+1] + 467.0.

[0574] Step 10: N-((1S)-2-((2-amino-2-isopropyl-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexane 2-(2-(2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide

[0575]

[0576] To a solution of 5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid (60 mg, 0.13 mmol) in toluene (5 mL) was added DPPA (53 mg) and TEA (0.1 mL). The mixture was heated to 90 ° C and stirred for 1 hour. The reaction mixture was cooled and concentrated to remove the solvent. The residue was dissolved in HCl acid (5 mL, 1N) and then stirred for 1 hour. The mixture was treated with NaHCO 3 The aqueous solution was basified to pH about 9 and extracted with EtOAc (10 mL x 3). The organic layer was washed with H 2 O, washed with brine, and MgSO 4 The residue was dried, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 1 / 1). N-((1S)-2-((2-amino-2-isopropyl-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide (30 mg, yield: 54%) was obtained. MS (ESI, m / e) [M+1] + 438.1.

[0577] Step 11: ((1-(((5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)- tert-Butyl (2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)methyl)cyclopropyl)methyl)carbamate

[0578]

[0579] N-((1S)-2-((2-amino-2-isopropyl-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide (30 mg, 0.069 mmol), tert-butyl ((1-formylcyclopropyl)methyl)carbamate (14 mg, 0.069 mmol) and NaBH(OAc) were added. 3 A mixture of 4-(50 mg)-1-(4-(4-piperidin-2-yl)-1-nitropropene)-2-nitropropene ... 2 O, washed with brine. The organic layer was separated and purified by MgSO 4 Dry, filter and concentrate in vacuo. The residue is purified by preparative TLC (eluent: DCM / MeOH (v / v) = 15:1). Tert-butyl ((1-(((5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)methyl)cyclopropyl)methyl)carbamate (20 mg, yield: 47%) is obtained. MS (ESI, m / e) [M+1] + 621.1.

[0580] Step 12: N-((1S)-2-((2-(((1-(aminomethyl)cyclopropyl)methyl)amino)-2-isopropyl-2,3-dihydro- (1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide

[0581]

[0582] Tert-butyl ((1-(((5-((S)-2-cyclohexyl-2-(1-methyl-1H-pyrazole-5-carboxamido)acetamido)-2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)methyl)cyclopropyl)methyl)carbamate (20 mg) was dissolved in HCl solution (10 mL, 2M in dioxane) and stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo to give N-((1S)-2-((2-(((1-(aminomethyl)cyclopropyl)methyl)amino)-2-isopropyl-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide salt of HCl (20 mg crude material). MS (ESI, m / e) [M+1] + 521.3.

[0583] Step 13: N-((1S)-1-cyclohexyl-2-((2-isopropyl-2-(6-oxo-5,7-diazaspiro[2.5]octane-5-yl)- (2,3-dihydro-1H-inden-5-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide (Example 170)

[0584] To a solution of N-((1S)-2-((2-(((1-(aminomethyl)cyclopropyl)methyl)amino)-2-isopropyl-2,3-dihydro-1H-inden-5-yl)amino)-1-cyclohexyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide (20 mg) and TEA (0.5 mL) in THF (5 mL) was added CDI (20 mg). The mixture was heated to reflux with stirring for 3 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by preparative TLC (eluent: DCM / MeOH (v / v)=15:1). The title compound (10 mg, yield in 2 steps: 28.6%) was obtained. 1 H NMR (400 MHz, DMSO-d 6 )δppm:10.05(s,1H),8.45(d,J=8.0Hz,1H),7.45(t,J=8.6Hz,2H),7.29(s,1H),7.04(d,J=10.4Hz,2H),6.05(s,1H),4.44-4.31(m,1H), 4.03(s,3H),3.21-2.92(m,4H),2.86(s,2H),2.67(s,2H),1.94-1.49(m,8H),128-1.15(m,4H),0.70(d,J=6.6Hz,6H),0.52-0.38(m,4H). MS(ESI,m / e)[M+1] + 547.7.

[0585] Example 212: N-((2S)-1,1-dicyclopropyl-3-((2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)-4-methyl-1,2,5-oxadiazole-3-carboxamide

[0586]

[0587] Step 1: 2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0588]

[0589] At 0 ° C, sodium hydride (8.8 g of oil containing 60% suspension, 222 mmol) was added portionwise to a solution of 1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (14 g, 73.6 mmol) in anhydrous DMF (250 ml) over 20 minutes. After the mixture was further stirred for 45 minutes, 2-iodopropane (25 g, 148 mmol) was added dropwise over 15 minutes. The mixture was then heated to 90 ° C and stirred for 18 hours. The reaction mixture was cooled to room temperature, then poured into ice / water (100 mL) and extracted with EA (100 mL×3). The combined organic layers were purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The residue was purified by silica gel column chromatography (eluent: PE / EA (v / v) = 10 / 1). 2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (8 g, 50%) was obtained. MS (ESI, m / e) [M+1] + 233.1.

[0590] Step 2: 1-Hydroxy-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0591]

[0592] To a solution of methyl 2-isopropyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (1.8 g, 7.8 mmol) in MeOH (50 mL) was added NaBH in portions at 0 °C. 4 (1.2 g, 32 mmol). The mixture was stirred for 1 hour and then concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic layer was washed with MgSO 4 Dry, filter and concentrate in vacuo. 1-Hydroxy-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (1.8 g, crude material) was obtained and used directly in the next step. MS (ESI, m / e) [M-17] + 217.1.

[0593] Step 3: 2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester

[0594]

[0595] Triethylsilane (5 mL) was added to a solution of 1-hydroxy-2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (1.7 g, 7.2 mmol) in TFA (25 mL). The mixture was stirred at room temperature for 1 hour. The reaction mixture was then concentrated under reduced pressure to remove the solvent. The residue was dissolved in DCM (25 mL) and saturated with NaHCO 3The organic layer was washed with brine and filtered through MgSO 4 Dry and concentrate in vacuo. 2-Isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (1.5 g, crude material) was obtained and used directly in the next step. MS (ESI, m / e) [M+1] + 219.1.

[0596] Step 4: 2-Isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid

[0597]

[0598] To a solution of methyl 2-isopropyl-2,3-dihydro-1H-indene-2-carboxylate (218 mg, 1 mmol) in methanol (3 mL) was added aqueous NaOH (1.0 N, 2 mL, 2 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was then acidified with HCl acid (2.0 N) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine, H 2 O washed with MgSO 4 Dry, filter and concentrate in vacuo to obtain 2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid (200 mg, crude material). MS (ESI, m / e) [M+1] + 205.1.

[0599] Step 5: 2-Isopropyl-2,3-dihydro-1H-inden-2-amine

[0600]

[0601] To a solution of 2-isopropyl-2,3-dihydro-1H-indene-2-carboxylic acid (1.2 g, 6.8 mmol) in toluene (25 mL) was added DPPA (2.75 g) and TEA (3 mL). The mixture was heated to 90 ° C and stirred for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was diluted into HCl acid (1N, 15 mL) and then stirred for 1 hour. The mixture was treated with NaHCO 3 The mixture was basified to pH about 8-9 and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with H 2 O, washed with brine, and MgSO 4 Dry, filter and concentrate in vacuo. The residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 4 / 1). 2-isopropyl-2,3-dihydro-1H-inden-2-amine (700 mg, yield: 69%) was obtained. MS (ESI, m / e) [M+1] + 176.1

[0602] Step 6: (1,1,1-trifluoro-3-((2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)-3-oxopropane- tert-Butyl 2-aminocarbamate

[0603]

[0604] To a mixture of 2-(((benzyloxy)carbonyl)amino)-3,3,3-trifluoropropionic acid (1.17 g, 4.8 mmol), HATU (1.98 g, 5.2 mmol) in DCM (30 mL) at 0°C was added 2-isopropyl-2,3-dihydro-1H-inden-2-amine (700 mg, 4 mmol) and TEA (1.6 g, 15.4 mmol). The mixture was stirred at room temperature for 1.5 hours. The reaction mixture was diluted with DCM and treated with NaHCO 3 The aqueous solution was quenched. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 5 / 1). Tert-butyl (1,1,1-trifluoro-3-((2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)-3-oxopropan-2-yl)carbamate (750 mg, yield: 46%) was obtained. MS (ESI, m / e) [M+1] + 401.1.

[0605] Step 7: (1,1,1-trifluoro-3-((2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)propan-2-yl)amino Tert-Butyl Formate

[0606]

[0607] To a solution of tert-butyl (1,1,1-trifluoro-3-((2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)-3-oxopropan-2-yl)carbamate (750 mg, 1.8 mmol) in THF (10 mL) was added BH 3 -Me 2 S (10mL). The mixture was heated to 70 ° C and stirred for 4 hours. The reaction mixture was quenched with MeOH (10mL). After removing the solvent, the residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 4 / 1). (1,1,1-trifluoro-3-((2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)propan-2-yl)carbamic acid tert-butyl ester (500mg, 72%) was obtained. MS (ESI, m / e) [M+1] + 387.2

[0608] Step 8: 3,3,3-Trifluoro-N 1 -(2-isopropyl-2,3-dihydro-1H-inden-2-yl)propane-1,2-diamine

[0609]

[0610] To a solution of tert-butyl (1,1,1-trifluoro-3-((2-isopropyl-2,3-dihydro-1H-inden-2-yl)amino)propan-2-yl)carbamate (500 mg) in THF was added HCl in dioxane (2M, 10 mL). The mixture was stirred at room temperature for 1 hour. After the solvent was removed in vacuo, 3,3,3-trifluoro-N 1 -(2-isopropyl-2,3-dihydro-1H-inden-2-yl)propane-1,2-diamine salt (450 mg, crude) which was used directly in the next step.

[0611] Step 9: 1-(2-isopropyl-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one

[0612]

[0613] CDI (324 mg, 2 mmol) was added to a solution of 3,3,3-trifluoro-N1-(2-isopropyl-2,3-dihydro-1H-inden-2-yl)propane-1,2-diamine (400 mg, 1.4 mmol) and TEA (1.5 mL) in THF (15 mL). The mixture was heated to reflux with stirring for 3 hours. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 5 / 1). 1-(2-isopropyl-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (150 mg, yield of 2 steps: 34%) was obtained. MS (ESI, m / e) [M+1] + 313.0.

[0614] Step 10: 1-(2-isopropyl-5-nitro-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidine-2-yl ketone

[0615]

[0616] At 0°C, H 2 SO 4 (2 mL) and HNO 3 To the mixture of 1-(2-isopropyl-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (80 mg, 0.25 mmol) in HOAc (2 mL) was added portionwise. The mixture was stirred at 0°C for 5 min and then washed with saturated NaHCO 3 The solution was quenched with aqueous solution (10 mL) and extracted with DCM (10 mL×3). The organic layer was washed with H 2 O, washed with brine, and MgSO 4Dry, filter and concentrate in vacuo. The residue was purified by silica gel column chromatography (eluent: hexane / EtOAc (v / v) = 4 / 1). 1-(2-isopropyl-5-nitro-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (40 mg, yield: 44%) was obtained. MS (ESI, m / e) [M+1] + 358.0.

[0617] Step 11: 1-(5-amino-2-isopropyl-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidine-2-yl ketone

[0618]

[0619] To a solution of 1-(2-isopropyl-5-nitro-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (40 mg, 0.11 mmol) in MeOH (10 mL) was added Pd / C (10 mg). The mixture was stirred under H 2 Stir for 1 hour under atmosphere. Filter the reaction mixture and concentrate the filtrate in vacuo. Obtain 1-(5-amino-2-isopropyl-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (40 mg, crude material). MS (ESI, m / e) [M+1] + 328.0.

[0620] Step 12: ((2S)-1,1-dicyclopropyl-3-((2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazolidine- tert-Butyl (1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate

[0621]

[0622] To a solution of 1-(5-amino-2-isopropyl-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (40 mg, 0.11 mmol) in DCM was added (S)-2-((tert-butoxycarbonyl)amino)-3,3-dicyclopropylpropionic acid (30 mg, 0.11 mmol), HATU (63 mg, 0.17 mmol) and TEA (0.1 mL). The mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated and purified by preparative TLC to give tert-butyl ((2S)-1,1-dicyclopropyl-3-((2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate (30 mg, yield: 47%). MS (ESI, m / e) [M+1] + 579.1.

[0623] Step 13: (2S)-2-amino-3,3-dicyclopropyl-N-(2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazole (2,3-dihydro-1H-inden-5-yl)propanamide

[0624]

[0625] To a solution of tert-butyl ((2S)-1,1-dicyclopropyl-3-((2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate (30 mg) in THF was added dioxane (2M, 10 mL) containing HCl. The mixture was stirred at room temperature for 1 hour. After the solvent was removed in vacuo, (2S)-2-amino-3,3-dicyclopropyl-N-(2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)propanamide (20 mg, crude material) was obtained. MS (ESI, m / e) [M+1] + 479.1.

[0626] Step 14: N-((2S)-1,1-dicyclopropyl-3-((2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazole alkyl-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)-4-methyl-1,2,5-oxadiazole-3-carboxylic Amide (Example 212)

[0627] To a solution of (2S)-2-amino-3,3-dicyclopropyl-N-(2-isopropyl-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)propanamide (20 mg, 0.042 mmol) in DCM (10 mL) was added 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (5 mg, 0.042 mmol), HATU (24 mg, 0.063 mmol) and TEA (0.1 mL). The mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to remove the solvent. The residue was purified by preparative TLC (eluent: DCM / CH3OH (v / v)=20 / 1). The title compound Example 212 (8 mg, yield: 32%) was obtained. 1 H NMR (400 MHz, DMSO-d 6 )δppm:10.06(s,1H),9.02(d,J=8.8Hz,1H),7.46(d,J=7.8Hz,1H),7.33(d,J=8.2Hz,1H),7.22(s,1H),7.12(d,J=8.0Hz,1H),4.89-4.80(m,1H), 4.24(s,1H),3.65(d,J=10.6Hz,1H),3.49-3.41(m,2H),3.09-3.01(m,3H ),2.59-2.53(m,1H),2.48(s,3H),0.94-0.76(m,9H),0.50-0.11(m,8H). MS(ESI,m / e)[M+1] + 589.5.

[0628] Embodiment 238

[0629] N-((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)-4-methyl-1,2,5-oxadiazole-3-carboxamide

[0630]

[0631] Step 1: (R)-1-(2-(Hydroxymethyl)-2,3-dihydro-1H-inden-2-yl)-4-isopropylimidazolidin-2-one.

[0632]

[0633] At 0°C, in N 2 To a solution of (R)-2-(4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (430 mg, 1.4 mmol, prepared by a procedure similar to 2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-methyl-5-nitro-2,3-dihydro-1H-indene-2-carboxamide described in Intermediate A2) in THF (8 mL) was added a solution of LAH (2.5 M, 1.5 mL, 3.7 mmol) dropwise under stirring at 4 °C. After the addition, the mixture was stirred at 0 °C for 1 hour. The reaction mixture was passed through Na 2 SO 4 The aqueous solution was quenched and extracted with EA (15 mL x 3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo. The residue was purified by preparative TLC (eluent: DCM / MeOH (v / v) = 20 / 1) to give (R)-1-(2-(hydroxymethyl)-2,3-dihydro-1H-inden-2-yl)-4-isopropylimidazolidin-2-one (270 mg, yield: 69%). MS (ESI) m / e [M+1] + 275.1.

[0634] Step 2: (R)-2-(4-Isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carbaldehyde.

[0635]

[0636] To a solution of (R)-1-(2-(hydroxymethyl)-2,3-dihydro-1H-inden-2-yl)-4-isopropylimidazolidin-2-one (270 mg, 1.0 mmol) in DCM (20 mL). The resulting solution was cooled to 0 ° C under a nitrogen atmosphere, and Dess-Martin reagent (636 mg, 1.5 mmol) was added in portions at 0 ° C under a nitrogen atmosphere. The mixture was stirred at room temperature for 2 hours. The reaction mixture was passed through Na 2 S 2 O 3 The aqueous solution (5 mL) was quenched at 0 °C and then treated with NaHCO 3 The mixture was diluted with aqueous solution (10 mL) and extracted with EA (15 mL×3). The combined organic layers were washed with brine, dried and concentrated in vacuo. The residue was purified by preparative TLC (eluent: DCM / MeOH (v / v)=30 / 1) to give (R)-2-(4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carbaldehyde (240 mg, yield: 88%). MS (ESI) m / e[M+1] + 273.1.

[0637] Step 3: (4R)-4-isopropyl-1-(2-(2,2,2-trifluoro-1-((trimethylsilyl)oxy)ethyl)-2, 3-dihydro-1H-inden-2-yl)imidazolidin-2-one.

[0638]

[0639] To a solution of (R)-2-(4-isopropyl-2-oxoimidazolidin-1-yl)-2,3-dihydro-1H-indene-2-carbaldehyde (240 mg, 0.88 mmol) in THF (10 mL) was added CsF (174 mg, 1.15 mmol) under nitrogen atmosphere. The resulting mixture was cooled to 0°C. To this mixture was added TMS-CF 3 (163 mg, 1.15 mmol). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with EtOAc (50 mL) and then washed with brine. The organic layer was separated and purified by Na 2 SO 4 Dry and concentrate in vacuo to afford (4R)-4-isopropyl-1-(2-(2,2,2-trifluoro-1-((trimethylsilyl)oxy)ethyl)-2,3-dihydro-1H-inden-2-yl)imidazolidin-2-one (300 mg, crude) which was used directly in the next step.

[0640] Step 4: (4R)-4-isopropyl-1-(2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-2-yl) Imidazolidin-2-one.

[0641]

[0642] (4R)-4-isopropyl-1-(2-(2,2,2-trifluoro-1-((trimethylsilyl)oxy)ethyl)-2,3-dihydro-1H-inden-2-yl)imidazolidin-2-one (300 mg, crude material) was dissolved in THF (10 mL) and cooled to 0°C. To this solution was added TBAF (0.1 mL, 1 M). The mixture was stirred at 0°C for 1 hour. The reaction mixture was diluted with EtOAc (50 mL) and then washed with brine. The organic layer was separated and purified by Na 2 SO 4 Dry and concentrate in vacuo. The residue was purified by preparative TLC (eluent: DCM / MeOH (v / v) = 25 / 1) to give (4R)-4-isopropyl-1-(2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-2-yl)imidazolidin-2-one (60 mg, yield for two steps: 20%). MS (ESI) m / e [M+1] + 343.2.

[0643] Step 5: (4R)-1-(5-amino-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-2-yl)- 4-Isopropylimidazolidin-2-one.

[0644]

[0645] At -5°C, 2 SO 4 (1 mL) and HNO 3 A solution of (4R)-4-isopropyl-1-(2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-2-yl)imidazolidin-2-one (60 mg) in AcOH (2 mL) was added in portions to the mixture of 4% paraformaldehyde (1.5 mL). The mixture was further stirred at -5 °C for 5 minutes. The reaction mixture was poured into water / ice and then extracted with EtOAc (15 mL × 3). The combined organic layers were washed with water, NaHCO 3 The mixture was washed with aqueous solution and brine, dried and concentrated in vacuo. (4R)-1-(5-amino-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-2-yl)-4-isopropylimidazolidin-2-one (70 mg, crude material) was obtained. The crude nitro product was dissolved in MeOH (10 mL) and treated with H in the presence of Pd / C (35 mg) at room temperature. 2 Stir and hydrogenate for 1 hour to obtain (4R)-1-(5-amino-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-2-yl)-4-isopropylimidazolidin-2-one (40 mg, crude material). MS (ESI) m / e [M+1] + 358.3.

[0646] Step 6: ((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(2, Benzyl (2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate.

[0647]

[0648] To a solution of (4R)-1-(5-amino-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-2-yl)-4-isopropylimidazolidin-2-one (40 mg, crude) in DCM (5 mL) was added (S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionic acid (34 mg, 0.11 mmol), DIPEA (43.4 mg, 0.34 mmol) and HATU (55.4 mg, 0.15 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM (15 mL) and then washed with NaHCO 3 The mixture was washed with water. The organic layer was washed with brine, dried and concentrated in vacuo. The crude product was purified by preparative TLC (eluent: EA / PE (v / v) = 1 / 1). Benzyl ((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-indene-5-yl)amino)-3-oxopropyl-2-yl)carbamate (30 mg, yield: 42%) was obtained. MS (ESI) m / e [M+1] + 643.5.

[0649] Step 7: (2S)-2-amino-3,3-dicyclopropyl-N-(2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)- 2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-5-yl)propanamide

[0650]

[0651] To a solution of benzyl ((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate (30 mg, 0.05 mmol) in MeOH was added Pd / C (30 mg). This mixture was then treated with H 2 Degas and store in H 2 The mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. The reaction mixture was diluted with DCM and filtered. The filtrate was concentrated to give (2S)-2-amino-3,3-dicyclopropyl-N-(2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-5-yl)propanamide (29 mg, crude material). MS (ESI) m / e [M+1]+ 509.4.

[0652] Step 8: N-((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2- (2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)-4-methyl-1,2, 5-oxadiazole-3-carboxamide (Example 238).

[0653] To a solution of (2S)-2-amino-3,3-dicyclopropyl-N-(2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(2,2,2-trifluoro-1-hydroxyethyl)-2,3-dihydro-1H-inden-5-yl)propanamide (29 mg, crude) in DCM (5 mL) was added 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (7.3 mg, 0.06 mmol), DIPEA (22 mg, 0.17 mmol) and HATU (33 mg, 0.09 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM (15 mL) and then washed with NaHCO 3 The organic layer was washed with brine, dried and concentrated in vacuo. The residue was first purified by preparative TLC. The crude product was then purified by preparative HPLC (mobile phase: MeCN / water (0.1% FA); column: SunFire; eluent: 60%-80% MeCN). The title compound Example 238 (8.16 mg, 28% for two steps) was obtained. 1 H NMR (400 MHz, DMSO-d 6 )δppm:10.12(s,1H),9.05(d,J=8.8Hz,1H),7.54-7.50(m,1H),7.43-7.32(m ,1H),7.24-7.11(m,1H),6.90-6.76(m,1H),4.87-4.75(m,2H),3.53-3.38(m ,3H),3.31-3.14(m,4H),2.97-2.89(m,1H),2.49(s,3H),1.37-1.24(m,1H), 0.93-0.67(m,3H),0.63-0.50(m,6H),0.49-0.35(m,2H),0.33-0.08(m,6H). MS (ESI) m / e [M+1] + 619.5.

[0654] Example 256: N-((2S)-1,1-dicyclopropyl-3-oxo-3-((2-(((S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)methyl)-2,3-dihydrobenzofuran-6-yl)amino)propan-2-yl)-1-isopropyl-1H-pyrazole-5-carboxamide

[0655]

[0656] Step 1: 2-(2,2-dimethoxyethoxy)-4-nitrobenzaldehyde

[0657]

[0658] To a solution of 2-hydroxy-4-nitrobenzaldehyde (10 g, 29.92 mmol) in DMA (100 mL) was slowly added 2-bromo-1,1-dimethoxyethane (40 g, 239.35 mmol), K 2 CO 3 (33 g, 239.35 mmol). The mixture was stirred at 140 ° C for 12 hours. The reaction mixture was poured into ice water (500 mL). The precipitate was collected by filtration and washed with water (500 mL). After vacuum drying the filter cake, 2-(2,2-dimethoxyethoxy)-4-nitrobenzaldehyde (10 g, yield: 66%) was obtained. 1 H NMR (400 MHz, CDCl 3 )δppm 10.55(s,1H),8.04-7.96(m,1H),7.94-7.86(m,2H),4.81(t,J=5.2Hz,1H),4.23(d,J=5.2Hz,2H),3.52-3.44(m,6H).

[0659] Step 2: 6-Nitrobenzofuran-2-carbaldehyde

[0660]

[0661] A solution of 2-(2,2-dimethoxyethoxy)-4-nitrobenzaldehyde (10 g, 39.18 mmol) in AcOH (100 mL) was heated to 60°C and stirred for 12 hours. The reaction mixture was concentrated under reduced pressure. The residue was poured into saturated Na 2 CO 3 The solution was added into an aqueous solution (100 mL), and then extracted with DCM (100 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate in vacuo to obtain 6-nitrobenzofuran-2-carbaldehyde (6 g, yield: 80%). 1 H NMR (400 MHz, CDCl 3 )δppm9.99(s,1H),8.52(s,1H),8.28(dd,J=2.0,8.8Hz,1H),7.92(d,J=8.8Hz,1H),7.65(d,J=0.4Hz,1H).

[0662] Step 3: (S)-3,3,3-trifluoro-N 1 -((6-Nitrobenzofuran-2-yl)methyl)propane-1,2-diamine

[0663]

[0664] To a solution of 6-nitrobenzofuran-2-carbaldehyde (2 g, 10.46 mmol) in i-PrOH (40 mL) at 20°C, (S)-3,3,3-trifluoropropane-1,2-diamine hydrochloride (2.58 g, 15.70 mmol) and TEA (4.24 g, 41.85 mmol) were added. The mixture was stirred at 60°C for 2 hours. After TLC indicated that the aldehyde reactant was completely consumed, AcOH (3.14 g, 52.30 mmol) and NaBH were added at 0°C. 3 CN (1.64 g, 26.16 mmol) was added to the reaction mixture (containing mainly the imine intermediate of (S)-1,1,1-trifluoro-3-(((6-nitrobenzofuran-2-yl)methylene)amino)propan-2-amine in i-PrOH). After the addition, the reaction mixture was further stirred at 80 °C for 12 h. The reaction mixture was cooled and then poured into saturated NaHCO 3 The solution was added into aqueous solution (20 mL) and extracted with DCM (50 mL×3). The combined layers were washed with brine and dried over anhydrous Na 2 SO 4 The residue was dried, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 100 / 1 to 0 / 1). (S)-3,3,3-trifluoro-N 1 -((6-Nitrobenzofuran-2-yl)methyl)propane-1,2-diamine (2.3 g, 70% yield). 1 H NMR (400 MHz, CDCl 3 )δppm 8.37(d,J=1.2Hz,1H),8.18(dd,J=2.0,8.4Hz,1H),7.63(d,J=8.4Hz,1H),6.74(s,1H),4.05( s, 2H), 3.36 (s, 1H), 3.37 (s, 1H), 3.00 (dd, J = 3.6, 12.4Hz, 1H), 2.75 (dd, J = 8.8, 12.0Hz, 1H). MS(ESI,m / e)[M+1] + 303.2.

[0665] Step 4: (S)-1-((6-nitrobenzofuran-2-yl)methyl)-4-(trifluoromethyl)imidazolidin-2-one

[0666]

[0667] At room temperature, (S)-3,3,3-trifluoro-N 1-((6-nitrobenzofuran-2-yl)methyl)propane-1,2-diamine (2.3 g, 7.58 mmol) in THF (20 mL) was added CDI (1.84 g, 11.38 mmol). The mixture was stirred at 80 ° C for 2 hours. The reaction mixture was cooled and poured into water (20 mL) and extracted with DCM (20 mL×3). The combined organic layer was washed with brine and washed with anhydrous Na 2 SO 4 The mixture was dried, filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v) = 50 / 1 to 1 / 1). (S)-1-((6-nitrobenzofuran-2-yl)methyl)-4-(trifluoromethyl)imidazolidin-2-one (1.5 g, yield: 60%) was obtained. 1 H NMR (400 MHz, CDCl 3 )δppm 8.42-8.35(m,1H),8.23-8.15(m,1H),7.67-7.62(m,1H),6.81-6.75(m,1H), 5.01-4.94(m,1H),4.68-4.54(m,1H),4.24-4.17(m,1H),3.84-3.62(m,2H).

[0668] Step 5: (4S)-1-((6-amino-2,3-dihydrobenzofuran-2-yl)methyl)-4-(trifluoromethyl)imidazolidine- 2-Keto

[0669]

[0670] To a solution of (S)-1-((6-nitrobenzofuran-2-yl)methyl)-4-(trifluoromethyl)imidazolidin-2-one (1.5 g, 4.56 mmol) in i-PrOH (10 mL) was added Pd / C (180 mg) at room temperature. The mixture was stirred and heated under H 2 Atmosphere (50psi) at 50 ℃ hydrogenation 12 hours.The reaction mixture is filtered and concentrated in vacuo.The crude product is purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate (v / v)=100 / 1 to 0 / 1).(4S)-1-((6-amino-2,3-dihydrobenzofuran-2-yl)methyl)-4-(trifluoromethyl)imidazolidin-2-one (810mg, yield: 59%) is obtained. 1 H NMR (400 MHz, CDCl 3)δppm 6.92(d,J=7.6Hz,1H),6.30-6.11(m,2H),5.16-4.88(m,2H),4.18-4.07(m,1H),3.84-3.71(m,1H),3. 67-3.54(m,3H),3.47-3.29(m,1H),3.18(ddd,J=3.2,9.6,15.2Hz,1H),2.86(dt,J=7.2,16.4Hz,1H). MS(ESI,m / e)[M+1] + 302.1.

[0671] Step 6: ((2S)-1,1-dicyclopropyl-3-oxo-3-((2-(((S)-2-oxo-4-(trifluoromethyl)imidazole (2-(4-(2-( ...

[0672]

[0673] To a solution of (4S)-1-((6-amino-2,3-dihydrobenzofuran-2-yl)methyl)-4-(trifluoromethyl)imidazolidin-2-one (301 mg, 1.0 mmol) in DCM (100 mL) was added (S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionic acid (303 mg, 1.0 mmol), HATU (380 mg, 1.0 mmol) and TEA (202 mg, 2.0 mmol). The mixture was stirred at room temperature for 4 h. The reaction mixture was then treated with NaHCO 3 (aqueous solution, 150 mL). The organic layer was separated, washed with brine, and washed with anhydrous Na 2 SO 4 The mixture was dried, filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 50 / 1). Benzyl ((2S)-1,1-dicyclopropyl-3-oxo-3-((2-(((S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)methyl)-2,3-dihydrobenzofuran-6-yl)amino)propane-2-yl)carbamate (469 mg, 80%) was obtained. MS (ESI, m / e) [M+1] + 587.2.

[0674] Step 7: (2S)-2-amino-3,3-dicyclopropyl-N-(2-(((S)-2-oxo-4-(trifluoromethyl)imidazolidine- 1-yl)methyl)-2,3-dihydrobenzofuran-6-yl)propanamide

[0675]

[0676] To a mixture of benzyl ((2S)-1,1-dicyclopropyl-3-oxo-3-((2-(((S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)methyl)-2,3-dihydrobenzofuran-6-yl)amino)propan-2-yl)carbamate (469 mg, 0.8 mmol) and Pd / C (50 mg) in MeOH (50 mL) was added H 2 The mixture was stirred for 2 hours under balloon bubbling. The mixture was filtered and concentrated in vacuo. The crude product (2S)-2-amino-3,3-dicyclopropyl-N-(2-(((S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)methyl)-2,3-dihydrobenzofuran-6-yl)propanamide (226 mg, crude product) was obtained and used directly in the next step. MS (ESI, m / e) [M+1] + 453.2.

[0677] Step 8: N-((2S)-1,1-dicyclopropyl-3-oxo-3-((2-(((S)-2-oxo-4-(trifluoromethyl)imidazole (2-(2-((2-(((((((((((((((((- ... (Example 256)

[0678] To a solution of (2S)-2-amino-3,3-dicyclopropyl-N-(2-(((S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)methyl)-2,3-dihydrobenzofuran-6-yl)propanamide (226 mg, 0.5 mmol) in DCM (50 mL) was added 1-isopropyl-1H-pyrazole-5-carboxylic acid (14 mg, 0.09 mmol), HATU (40 mg, 0.09 mmol) and DIEA (23 mg, 0.18 mmol). The mixture was stirred at room temperature for 4 h. The reaction mixture was washed with saturated NaHCO 3 The organic layer was separated, washed with brine, and washed with anhydrous Na 2 SO 4 The mixture was dried, filtered and concentrated in vacuo. The residue was purified by preparative TLC (eluent: MeOH / DCM (v / v) = 1 / 20) to give a crude product. The crude product was purified by preparative HPLC. N-((2S)-1,1-dicyclopropyl-3-oxo-3-((2-(((S)-2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)methyl)-2,3-dihydrobenzofuran-6-yl)amino)propane-2-yl)-1-isopropyl-1H-pyrazole-5-carboxamide (16.85 mg, 32.3%) was obtained. 1 H NMR (400 MHz, DMSO-d 6)δppm:10.09(d,J=5.0Hz,1H),8.42(d,J=8.7Hz,1H),7.52-7.50(m,2H),7.18(d,J=4.4Hz ,1H),7.10(t,J=8.4Hz,1H),7.00(d,J=7.8Hz,1H),6.92(s,1H),5.44-5.37(m,1H),4.95-4 .93(m,1H),4.76(t,J=8.2Hz,1H),4.35(s,1H),3.79-3.66(m,1H),3.58-3.37(m,2H),3.30 -3.14(m,2H),2.87-2.82(m,1H),1.38-1.33(m,6H),0.89-0.67(m,3H),0.45-0.06(m,8H). MS(ESI,m / e)[M+1] + 589.5.

[0679] Example 261: N-((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(o-tolylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)-4-methyl-1,2,5-oxadiazole-3-carboxamide

[0680]

[0681] To a solution of 5-((S)-2-amino-3,3-dicyclopropylpropionamido)-2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-N-(o-tolyl)-2,3-dihydro-1H-indene-2-carboxamide (65 mg, 0.12 mmol) in DCM (5 mL) at 0°C was added 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (23 mg, 0.18 mmol), HATU (68 mg, 0.18 mmol) and DIEA (31 mg, 0.24 mmol). The mixture was stirred at room temperature for 12 hours. The reaction mixture was diluted with water (3 mL) and extracted with DCM (5 mL×3). The combined organic layers were washed with brine and purified by anhydrous Na 2 SO 4The mixture was dried, filtered and concentrated in vacuo. The crude product was purified by preparative HPLC (column: Phenomenex Luna C18 75*30mm*3um; mobile phase: [water (NH4HCO3)-ACN]; B%: 40%-70%, 8min). N-((2S)-1,1-dicyclopropyl-3-((2-((R)-4-isopropyl-2-oxoimidazolidin-1-yl)-2-(o-tolylcarbamoyl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropane-2-yl)-4-methyl-1,2,5-oxadiazole-3-carboxamide (15.5 mg, yield: 19.8%) was obtained. 1 H NMR (400 MHz, DMSO-d 6 )δppm 10.10(s,1H),9.07-8.96(m,2H),7.56-7.47(m,1H),7.46-7.32(m,2H),7.19(d,J=7.6Hz,2H),7.16-7.10( m,1H),7.08-7.03(m,1H),7.02(s,1H),4.86(t,J=8.0Hz,1H),3.70(t,J=17.6Hz,1H),3.62-3.49(m,2H),3 .48-3.38(m,1H),3.30-3.25(m,1H),3.22(d,J=16.4Hz,1H),2.94(td,J=7.6,12.4Hz,1H),2.49(s,3H),2. 17(s,3H),1.55-1.42(m,1H),0.93-0.84(m,1H),0.82-0.68(m,8H),0.52-0.36(m,2H),0.34-0.11(m,6H). MS(ESI,m / e)[M+1] + 654.2.

[0682] Example 279: N-((2S)-1,1-dicyclopropyl-3-((2-(2-hydroxypropan-2-yl)-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)-4-methyl-1,2,5-oxadiazole-3-carboxamide

[0683]

[0684] Step 1: 2-(2-Amino-2,3-dihydro-1H-inden-2-yl)propan-2-ol.

[0685]

[0686] 2-Amino-2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (1 g, 5.2 mmol) was dissolved in THF (20 mL) and stirred at N 2 To this solution, CH 3 MgBr (26.2 mL, 26.2 mmol). The mixture was warmed to room temperature and stirred for 30 minutes. 4 The Cl aqueous solution was quenched at 0°C and extracted with DCM (30 mL×3). The combined organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v)=10 / 1). 2-(2-amino-2,3-dihydro-1H-inden-2-yl)propan-2-ol (980 mg, yield: 98%) was obtained. MS (ESI) m / e[M+1] + 192.2.

[0687] Step 2: (1,1,1-trifluoro-3-((2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)-3- Benzyl 2-oxopropan-2-yl)carbamate.

[0688]

[0689] To a mixture of 2-(((benzyloxy)carbonyl)amino)-3,3,3-trifluoropropionic acid (1.4 g, 5.1 mmol), EDCI (2.5 g, 12.8 mmol) and HOBt (727 mg, 5.4 mmol) in DCM (30 mL) at 0°C was added 2-(2-amino-2,3-dihydro-1H-inden-2-yl)propan-2-ol (980 mg, 5.1 mmol) and TEA (1.6 g, 15.4 mmol). The mixture was warmed to room temperature and stirred for 1.5 hours. The reaction mixture was diluted with DCM and treated with NaHCO 3 The product was quenched with (aqueous solution). The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: PE / EA (v / v) = 1 / 1). (1,1,1-trifluoro-3-((2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-indene-2-yl)amino)-3-oxopropan-2-yl)benzyl carbamate (400 mg, yield: 17%) was obtained. MS (ESI) m / e [M+1] + 451.3.

[0690] Step 3: (1,1,1-trifluoro-3-((2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)propan- 2-yl)benzyl carbamate.

[0691]

[0692] Benzyl (1,1,1-trifluoro-3-((2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)-3-oxopropan-2-yl)carbamate (400 mg, 0.89 mmol) was added to BH 3 -THF (1M, 10mL). The mixture was heated to 60 ° C and stirred for 6 hours. The reaction mixture was cooled to room temperature and quenched by MeOH (5mL) at 0 ° C. The mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 25 / 1). (1,1,1-trifluoro-3-((2-(2-hydroxypropyl-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)propyl-2-yl)benzyl carbamate (110mg, yield: 28%) was obtained. MS (ESI) m / e [M+1] + 437.3.

[0693] Step 4: (3-((2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-indene- Benzyl 2-(1,2-yl)amino)-1,1,1-trifluoropropan-2-yl)carbamate.

[0694]

[0695] At 0°C, in N 2 To a solution of benzyl (1,1,1-trifluoro-3-((2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)propan-2-yl)carbamate (110 mg, 0.25 mmol) in DCM (5 mL) was added 2,6-lutidine (40.5 mg, 0.38 mmol) and TBS-OTf (86.6 mg, 0.33 mmol) dropwise under a 4% CO atmosphere. The mixture was stirred at 0° C. for 1 hour. The reaction mixture was purified by NaHCO 3 The aqueous solution (10 mL) was quenched at 0 ° C and extracted with EtOAc (10 mL × 3). The combined organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluent: PE / EA (v / v) = 3 / 1). (3-((2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)-1,1,1-trifluoropropan-2-yl)benzyl carbamate (110 mg, yield: 79%) was obtained. MS (ESI) m / e [M+1] + 551.4.

[0696] Step 5: N 1 -(2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-indene-2- 1,2-diamine.

[0697]

[0698] To a solution of benzyl (3-((2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-inden-2-yl)amino)-1,1,1-trifluoropropan-2-yl)carbamate (110 mg, 0.2 mmol) in MeOH (5 mL) was added Pd / C (55 mg). This mixture was then treated with H 2 Degas and store in H 2 Stir at room temperature for 1 hour under atmosphere. The reaction mixture was diluted with DCM (5 mL) and then filtered. The filtrate was concentrated in vacuo. 1 -(2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-inden-2-yl)-3,3,3-trifluoropropane-1,2-diamine (84 mg, crude material), which was used directly in the next step. MS (ESI) m / e [M+1] + 417.4.

[0699] Step 6: 1-(2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-indene- 2-yl)-4-(trifluoromethyl)imidazolidin-2-one.

[0700]

[0701] At room temperature, N 1 -(2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-inden-2-yl)-3,3,3-trifluoropropane-1,2-diamine (84 mg, 0.2 mmol) in THF (6 mL) was added CDI (82 mg, 0.5 mmol) and TEA (102 mg, 1.0 mmol). The mixture was heated to 60 ° C and stirred for 2 hours. The reaction mixture was then cooled to room temperature, diluted with EtOAc (20 mL) and washed with brine. The organic layer was dried and concentrated in vacuo. The residue was purified by preparative TLC (eluent: EtOAc / DCM (v / v)=2 / 1). 1-(2-(2-((tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (80 mg, crude material) was obtained. MS (ESI) m / e [M+1] + 443.3.

[0702] Step 7: 1-(2-(2-hydroxypropan-2-yl)-5-nitro-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazole Oxazolidin-2-one.

[0703]

[0704] At -5°C, 2 SO 4 (2 mL) and HNO 3To the mixture of 4-(tert-butyldimethylsilyl)oxy)propan-2-yl)-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (80 mg) in AcOH (2 mL) was added portionwise. The mixture was further stirred at -5°C for 5 minutes. The reaction mixture was poured into water / ice and then extracted with EtOAc (15 mL×3). The combined organic layers were washed with water, NaHCO 3 The mixture was washed with aqueous solution and brine, dried and concentrated in vacuo to give 1-(2-(2-hydroxypropan-2-yl)-5-nitro-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (50 mg, crude material). MS (ESI) m / e [M+23] + 374.2.

[0705] Step 8: 1-(5-amino-2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazole Oxazolidin-2-one.

[0706]

[0707] To a solution of 1-(2-(2-hydroxypropan-2-yl)-5-nitro-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (50 mg, crude) in MeOH (6 mL) was added Pd / C (30 mg). The mixture was then washed with H 2 Degas and stir at room temperature for 1 hour. The reaction mixture was diluted with DCM (15 mL) and filtered. The filtrate was concentrated in vacuo. 1-(5-amino-2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (40 mg, crude material) was obtained. MS (ESI) m / e [M+1] + 344.2.

[0708] Step 9: ((2S)-1,1-dicyclopropyl-3-((2-(2-hydroxypropan-2-yl)-2-(2-oxo-4-(trifluoromethyl) (4-(4-(4-(4-nitro-2-yl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamic acid benzyl ester.

[0709]

[0710] To a solution of 1-(5-amino-2-(2-hydroxypropan-2-yl)-2,3-dihydro-1H-inden-2-yl)-4-(trifluoromethyl)imidazolidin-2-one (40 mg, 0.11 mmol) in DCM (5 mL) was added (S)-2-(((benzyloxy)carbonyl)amino)-3,3-dicyclopropylpropionic acid (35 mg, 0.11 mmol), DIPEA (45 mg, 0.35 mmol) and HATU (66 mg, 0.17 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM (15 mL) and treated with NaHCO3 The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by preparative TLC (eluent: EtOAc / DCM (v / v) = 1 / 1). ((2S)-1,1-dicyclopropyl-3-((2-(2-hydroxypropane-2-yl)-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-indene-5-yl)amino)-3-oxopropane-2-yl)benzyl carbamate (30 mg, 3 step yield: 41%) was obtained. MS (ESI) m / e [M+1] + 629.1.

[0711] Step 10: (2S)-2-amino-3,3-dicyclopropyl-N-(2-(2-hydroxypropan-2-yl)-2-(2-oxo-4-(tri (fluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)propanamide.

[0712]

[0713] To a solution of benzyl ((2S)-1,1-dicyclopropyl-3-((2-(2-hydroxypropan-2-yl)-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)carbamate (30 mg, 0.05 mmol) in MeOH (6 mL) was added Pd / C (30 mg). The mixture was then treated with H 2 Degas and store in H 2 Stir for 1 hour under atmosphere. The reaction mixture was diluted with DCM (10 mL) and filtered. The filtrate was concentrated in vacuo. (2S)-2-amino-3,3-dicyclopropyl-N-(2-(2-hydroxypropan-2-yl)-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-indene-5-yl)propanamide (28 mg, crude material) was obtained. MS (ESI) m / e[M+1] + 495.2.

[0714] Step 11: N-((2S)-1,1-dicyclopropyl-3-((2-(2-hydroxypropan-2-yl)-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)amino)-3-oxopropan-2-yl)-4-methyl-1,2,5-oxadiazole-3-carboxamide (Example 279).

[0715]

[0716] To a solution of (2S)-2-amino-3,3-dicyclopropyl-N-(2-(2-hydroxypropan-2-yl)-2-(2-oxo-4-(trifluoromethyl)imidazolidin-1-yl)-2,3-dihydro-1H-inden-5-yl)propanamide (28 mg, crude material) in DCM (5 mL) was added 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (7.3 mg, 0.06 mmol), DIPEA (22 mg, 0.17 mmol) and HATU (33 mg, 0.09 mmol). The mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM (15 mL) and then washed with NaHCO 3 The mixture was washed with water. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was first purified by preparative TLC. The crude product was purified by preparative HPLC (mobile phase: MeCN / water (0.1% FA); column: SunFire; eluent: 50%-68% MeCN). The title compound Example 279 (10 mg, two-step yield: 29%) was obtained. 1 H NMR (400 MHz, DMSO-d 6 )δppm:10.06(s,1H),9.01(d,J=8.8Hz,1H),7.46(t,J=9.4Hz,1H),7.34-7.30(m,2H),7.12(d,J=7.8Hz,1H),5.21(s,1H),4.85(t, J=7.8Hz,1H),4.23(s,1H),3.83-3.57(m,3H),3.43-3.18(m,3H),2.48(s,3H),1.10(s,6H),0.93-0.62(m,3H),0.52-0.11(m,8H). MS(ESI)m / e[M+1] + 605.2.

[0717] Other examples were synthesized by methods similar to those known to those skilled in the art, such as Example 32 or Example 170, Example 212, Example 238, Example 256, Example 261, and Example 279. The corresponding compound names, structures, and spectral data are listed in the table.

[0718]

[0719]

[0720]

[0721]

[0722]

[0723]

[0724]

[0725]

[0726]

[0727]

[0728]

[0729]

[0730]

[0731]

[0732]

[0733]

[0734]

[0735]

[0736]

[0737]

[0738]

[0739]

[0740]

[0741]

[0742]

[0743]

[0744]

[0745]

[0746]

[0747]

[0748]

[0749]

[0750]

[0751]

[0752]

[0753]

[0754]

[0755]

[0756]

[0757]

[0758]

[0759]

[0760]

[0761]

[0762]

[0763]

[0764]

[0765]

[0766]

[0767]

[0768]

[0769]

[0770]

[0771]

[0772]

[0773]

[0774]

[0775]

[0776]

[0777]

[0778]

[0779]

[0780]

[0781]

[0782]

[0783]

[0784]

[0785]

[0786]

[0787]

[0788]

[0789]

[0790]

[0791]

[0792]

[0793]

[0794]

[0795]

[0796]

[0797]

[0798]

[0799]

[0800]

[0801]

[0802]

[0803] Bioassay:

[0804] The biological activity of the compounds of the present disclosure was determined using the assays described herein. The values ​​may fluctuate depending on the daily assay performance, and such fluctuations are known to those skilled in the art. These results show that the compounds of the present disclosure are able to inhibit the biological effects of IL-17A.

[0805] Human IL-17A biochemical assay

[0806] In a homogeneous time-resolved fluorescence-based assay, the compounds disclosed herein were tested for blocking human IL-17A (Cat: C774, new protein) protein with its receptor human IL-17RA (Cat: CI53, new protein). At room temperature, 0.4 nM recombinant human IL-17A protein was pre-incubated with serial dilutions of the compounds disclosed herein (maximum concentration of 10 uM, 2.7-fold serial dilutions, 10 points) in an assay buffer containing 20 mM HEPES, pH 7.5, 50 mM NaCl, 0.1% BSA, 0.2 mM DTT, 0.005% Tween 20 for 3 hours. Then 0.3 nM recombinant human IL-17RA was added to the plate and further incubated for 1 hour at room temperature. Thereafter, MAb anti-6His Tb cryptate Gold (Cat: 61HI2TLB, Cisbio Bioassays) and MAb anti-human IgG-XL665 (Cat: 61HFCXLB, Cisbio Bioassays) were added to the plate and further incubated for 1 hour at room temperature. HTRF signals (ex337 nm, em620 nm / 665 nm) were read on a BMG PHERAstar FSX instrument. The percentage inhibition of the interaction of human IL-17A with its receptor human IL-17RA in the presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 620 nm to fluorescence at 665 nm. The data were fitted to a four-parameter logistic equation by Dotmatics to obtain the IC50 for each compound.

[0807] GROα release assay in human colorectal adenocarcinoma epithelial cells

[0808] The purpose of this assay is to test the ability of compounds to neutralize the IL17A protein. IL17 can stimulate human epithelial cells to secrete GROα. In this assay a compound of the invention was tested for its ability to neutralize IL-17-induced GROα secretion from the human colorectal adenocarcinoma epithelial cell line HT-29.

[0809] HT-29 cells (human colorectal adenocarcinoma epithelial cells, ATCC) were stimulated with IL-17A (Novoprotein, #C774) at a final concentration of 10 ng / mL. The resulting GROα response was measured using an ELISA kit from Invitrogen (#88-52122). HT-29 cells were cultured in complete medium (McCoy's 5A medium + 10% FBS) and maintained in tissue culture flasks using standard techniques. On day 1, cells were detached using TrypLE (Gibco, #12605036) and neutralized with complete medium. Cells were centrifuged at 11,00 rpm for 4 minutes. The cell pellet was resuspended in complete medium and 50,000 HT-29 cells were seeded into a 96-well assay plate (Corning, 3599) with 135 μL of complete medium per well. The cells were incubated at 37°C / 5% CO 2 Incubate overnight at 4 °C to allow the plates to adhere. On day 2, prepare 4-fold serial dilutions of the test compound in DMSO. The highest concentration of the compound is 10 μM. Transfer 2 μL of the serially diluted compound from the serial dilution plate to a reagent plate containing 198 μL of complete medium with 100 ng / mL IL-17A per well. Incubate the compound with IL-17A for 15 minutes. Transfer 15 μL of the mixture from the reagent plate to the cell assay plate. Incubate the plate at 37 °C / 5% CO 2 Incubate for 48 hours at 4°C. After incubation, on day 4, measure GROα levels using GROα ELISA as per manufacturer's instructions. Collect 50 μL of supernatant from the assay plate to the ELISA plate. Read the ELISA plate at 450 nm on a microplate reader and compare to a standard calibration curve.

[0810] Data were processed using GraphPad Prism. GROα concentrations were calculated from the standard curve. IC50s were determined using the equation log concentration (inhibitor) versus response and fitted to four parameters.

[0811]

[0812]

[0813]

[0814]

[0815]

[0816] It will be appreciated that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms part of the common general knowledge in the art in any country.

[0817] The disclosures of all publications, patents, patent applications, and published patent applications mentioned herein by identified reference are incorporated herein by reference in their entirety.

[0818] Although the foregoing invention has been described in some detail by way of illustration and example for the purpose of clear understanding, it is obvious to those skilled in the art that some minor changes and modifications will be implemented. Therefore, the description and examples should not be construed as limiting the scope of the invention.

Claims

1. A compound of formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a deuterated analog thereof, wherein: Cy1 is a 5-6 membered aromatic ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 3 replace; n3 is independently 0, 1, 2 or 3; Cy2 is a 4-8 membered saturated or partially or fully unsaturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is substituted by at least one substituent R 1 and / or R 2 replace; n1 is 0 or 1; n2 is 0, 1, or 2; n1 and n2 are not 0 at the same time; Cy1 and Cy2 are fused to each other; Cy3 is a 3-12 membered saturated or partially or fully unsaturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is optionally substituted by at least one substituent R 6 replace; n6 is independently 0, 1, 2, 3, 4 or 5, provided that the valence theory is satisfied; X 1 Is a single bond or -CR 9 R 10 -; R 1 Independently selected from H or Where X 2 is N or C (R 15 ); X 3 is -C(O)-, -S(O)- or -S(O)2-; n11 and n12 are each independently 1, 2 or 3; n14 is 0 or 1; R 15 Selected from hydrogen, halogen, -C 1-8 Alkyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -CN, -OR 15a 、-NR 15a R 15b or -NR 15a COR 15b ;-C 1-8 Each of the alkyl group, the C3-C8 cycloalkyl group and the 3-membered to 8-membered heterocyclic group is optionally substituted with at least one substituent R 15c replace; R 15a and R 15b are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 15d replace; R 15c and R 15d is independently halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, -C3-C8 halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl; R 11a , R 11b , R 12a and R 12b are each independently selected from hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -OR 11c 、-COR 11c 、-CO2R 11c 、-CONR 11c R 11d 、-NR 11c R 11d or -NR 11c COR 11d ;-C 1-8 Alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 11e Replace, or (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R 12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the atoms to which they are attached form a 3- to 8-membered unsaturated or saturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 11f replace; R 11e and R 11f is independently hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR 11g , thio (=S), -SR 11g 、-CN、-SO2R 11g 、-SO2NR 11g R 11h 、-COR 11g 、-CO2R 11h 、-CONR 11g R 11h 、-NR 11g R 11h 、-NR 11g COR 11h 、-NR 11g CO2R 11h or -NR 11g S02R 11h ;-C 1-8 Alkyl, -C 1-8 Alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 11i replace; R 11c , R 11d , R 11g and R 11h are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 11j replace; R 11i and R 11j is independently halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, -C3-C8 halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituted group, halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, -C3-C8 halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl substitution; R 13 , R 14a and R 14b are each independently selected from hydrogen, -C 1-8 Alkyl, -C3-C8 cycloalkyl or 3- to 8-membered heterocyclic group; -C 1-8 Each of the alkyl group, the -C3-C8 cycloalkyl group and the 3-membered to 8-membered heterocyclic group is optionally substituted with at least one substituent R 13a replace; R 13a is independently at each occurrence halogen, -OH, -CN, oxo, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, -C3-C8 halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl; R 2 Independently selected from H, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, C6-C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -COR 2a 、-CO2R 2a 、-CONR 2a R 2b 、-NR 2a R 2b or -NR 2a COR 2b , -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 2c replace; or When two adjacent or 2 When taken together with the carbon atoms to which they are attached to form a 3- to 8-membered unsaturated or saturated ring, the ring contains 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2c replace; R 2a and R 2b are each independently selected from hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 2d replace; or R 2a and R 2b Together with the nitrogen atom to which they are attached, they form a 3- to 8-membered unsaturated or saturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2d replace; R 2c and R 2d is independently hydrogen, halogen, -C 1-8 Alkyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR 2e 、-SR 2e 、-CN、-COR 2e 、-CO2R 2e 、-CONR 2e R 2f 、-NR 2e R 2f 、-NR 2e COR 2f or -NR 2e CO2R 2f ;-C 1-8 Alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 2g replace; R 2e and R 2f are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 2h replace; R 2g and R 2h is independently halogen, -OH, -C 1-8 Alkyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, -C3-C8 halogenated cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl; When n1 and n2 are both 1, R 1 and R 2 are concomitant or adjacent; R 3 are independently selected from hydrogen, halogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, -C3-C8 cycloalkyl or -CN, wherein -C 1-8 Alkyl, -C 1-8 Each of the alkoxy and -C3-C8 cycloalkyl groups is optionally substituted by at least one selected from halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 aryl or 5- to 12-membered heteroaryl substituents; R 4 is oxo (=O) or thio (=S); or R 3 and R 4 Together with the atoms to which they are attached, they form a 5- to 6-membered aromatic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 3a replace; R 3a are independently selected from hydrogen, halogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, -C3-C8 cycloalkyl or -CN, wherein -C 1-8 Alkyl, -C 1-8 Each of the alkoxy and -C3-C8 cycloalkyl groups is optionally substituted by at least one selected from halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 aryl or 5- to 12-membered heteroaryl substituents; R 5 It is C6-C 12 Aryl, 5- to 12-membered heteroaryl, -COR 5a 、-CO2R 5a 、-CONR 5a R 5b , among which C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 5c replace; R 5a and R 5b Each independently selected from -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 5d replace; or R 5a and R 5b Together with the atoms to which they are attached, they form a 3- to 8-membered unsaturated or saturated ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 5d replace; R 5c and R 5d is independently selected at each occurrence from hydrogen, halogen, -C 1-8 Alkyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR 5e 、-SR 5e 、-CN、-COR 5e 、-CO2R 5e 、-CONR 5e R 5f 、-NR 5e R 5f 、-NR 5e COR 5f or -NR 5e CO2R 5f ;-C 1-8 Alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 5g replace; R 5e and R 5f are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 5h replace; R 5g and R 5h are independently selected from halogen, -OH, -CN, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl; R 6 H, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, C6-C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -OR 6a 、-NR 6a R 6b 、-COR 6a 、-CO2R 6a 、-CONR 6a R 6b 、-COR 6a or -NR 6a COR 6b , -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 6c replace; R 6a and R 6b are each independently selected from hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 6d replace; R 6c is independently at each occurrence hydrogen, halogen, -C 1-8 Alkyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl 5- to 12-membered heteroaryl, oxo (=O), -OR 6e 、-SR 6e 、-CN、-COR 6e 、-CO2R 6e 、-CONR 6e R 6f 、-NR 6e R 6f 、-NR 6e COR 6f or -NR 6e CO2R 6f ;-C 1-8 Alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl or 5- to 12-membered heteroaryl groups is optionally substituted with at least one substituent R 6g replace; R 6e and R 6f are each independently selected from hydrogen, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C 12 Cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; R 6d and R 6g are each independently selected from halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl; R 7 and R 8 each independently is hydrogen; R 9 and R 10 are each independently selected from H, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, C6-C 12 Aryl or 5- to 12-membered heteroaryl, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 9a replace; and R 9a is independently at each occurrence halogen, -OH, -C 1-8 Alkyl, -C 1-8 Alkoxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl.

2. The compound of claim 1, wherein the compound is selected from the group consisting of formula (IIa)-(IIp): in, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy3, n1, n2, n3, n6 and X 1 As defined in claim 1.

3. The compound of claim 1, wherein the compound is selected from the group consisting of formula (IIf1)-(IIf2): in, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy3, n1, n2, n3, n6 and X 1 As defined in claim 1.

4. The compound of claim 1, wherein the compound is selected from formula (IIIa)-(IIIb): in, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy1, Cy2, Cy3, n1, n2, n3, n6, R 9 and R 10 As defined in claim 1.

5. The compound of claim 1, wherein the compound is selected from formula (IVa)-(IVb): in, X 1 , R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , Cy1, Cy2, Cy3, n1, n2, n3, n6, R 9 and R 10 As defined in claim 1.

6. The compound of claim 1, wherein the compound is selected from the group consisting of formula (Va)-(Vc): in, X 1 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 、Cy1、Cy2、Cy3、 n3, n6, R 9 and R 10 As defined in claim 1.

7. The compound of claim 1, wherein the compound is VIa, Preferably, the compound is selected from VIb and Vic in, X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Cy1, Cy2, Cy3, n2, n3, n6, R 11a , R 11b , R 12a , R 12b , R 13 , R 14a , R 14b , n11, n12 and n14 are as defined in claim 1.

8. The compound of claim 1, wherein the compound is VIIa or VIIb, Preferably, the compound is selected from VIIc, VIId, VIIe, VIIf, VIIg or VIIh, in, X 2 , R 2a , R 3 , R 5 , R 6 , R 9 , R 10 , Cy1, Cy2, Cy3, n2, n3, n6, R 11a , R 11b , R 12a , R 12b , R 13 , R 14a , R 14b , n11, n12 and n14 are as defined in claim 1.

9. A compound as claimed in any one of the preceding claims, wherein Cy1 is a 5- or 6-membered aromatic ring comprising 0, 1 or 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring being optionally substituted by 0, 1, 2 or 3 substituents R 3 replace; Preferably, Cy1 is phenyl, pyridyl, thienyl, imidazolyl, furanyl or pyrazolyl; each of phenyl, pyridyl, thienyl, imidazolyl, furanyl or pyrazolyl is optionally substituted by 0, 1 or 2 substituents R 3 replace.

10. A compound as claimed in any one of the preceding claims, wherein Cy2 is a 4-, 5-, 6-, 7- or 8-membered saturated or partially or fully unsaturated ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen or oxygen; wherein the ring is substituted by at least one substituent R 1 and / or R 2 replace; Preferably, Cy2 is a 5-, 6- or 7-membered saturated or partially or fully unsaturated ring, the ring containing 0, 1 or 2 heteroatoms independently selected from nitrogen or oxygen; the ring is substituted by at least one substituent R 1 and / or R 2 replace.

11. A compound as claimed in any one of the preceding claims, wherein Some selected from:

12. A compound as claimed in any one of the preceding claims, wherein Cy3 is a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11- or 12-membered saturated or partially or fully unsaturated ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is optionally substituted by 0, 1, 2, 3, 4 or 5 substituents R 6 replace; Preferably, Cy3 is a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11- or 12-membered saturated or partially or fully unsaturated ring, which is a monocyclic, bicyclic or tricyclic ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or optionally oxidized sulfur; the ring is optionally substituted by 0, 1, 2, 3, 4 or 5 substituents R 6 replace; More preferably, Part is Even more preferably, Part is 13. A compound as claimed in any one of the preceding claims, wherein R 1 Independently selected from H, Where R 11a , R 11b , R 12a , R 12b , R 13 , n11 and n12 are as defined in claim 1.

14. A compound as claimed in any one of the preceding claims, wherein R 15 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, -CN, -OR 15a 、-NR 15a R 15b or -NR 15a COR 15b ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and 3- to 8-membered heterocyclic groups are each optionally substituted with at least one substituent R 15c replace; R 15a and R 15b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C6-C 12 aryl or 5- to 12-membered heteroaryl, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C6-C 12 Each of the aryl group and the 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 15d replace; R 15c and R 15d is independently at each occurrence -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C8 halocycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

15. A compound as claimed in any one of the preceding claims, wherein R 15 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, -CN, -OH, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy; Preferably, R 15 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl; More preferably, R 15 is selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl; Even more preferably, R 15 Selected from hydrogen.

16. A compound as claimed in any one of the preceding claims, wherein R 11a , R 11b , R 12a and R 12b each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1 -enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-ynyl yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl , oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN;methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-1 , hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl , oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl are each optionally substituted with at least one substituent R; 11e replace; R 11e and -1-en-1-yl, -4-en-1-yl, -3-en-1-yl, -2-en-1-yl, -1-en-1-yl, -5 ... 1-enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1 -yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, alkynyl, oct-3-ynyl, oct-2-ynyl, oct-1-ynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxo (=O), -OR 11g , thio (=S), -SR 11g 、-CN、-SO2R 11g 、-SO2NR 11g R 11h 、-COR 11g 、-CO2R 11h 、-CONR 11g R 11h 、-NR 11g R 11h 、-NR 11g COR 11h 、-NR 11g CO2R 11h or -NR 11g S02R 11h ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en- yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent- 3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl, Each of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl is optionally substituted with at least one substituent R 11i replace; R 11c , R 11d , R 11g and R 11h are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 Haloalkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Each of alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, and 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 11j replace; R 11i and R 11j is independently at each occurrence -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-1-yl, yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1 yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1 -alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C8 halocycloalkyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-1-yl -enyl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl. yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C Each of 3-C8 halocycloalkyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl is optionally substituted with at least one -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 The cycloalkyl group may be substituted with an alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C8 halocycloalkyl, a 3- to 8-membered heterocyclyl, phenyl, or a 5- to 12-membered heteroaryl.

17. A compound as claimed in any one of the preceding claims, wherein R 11a , R 11b , R 12a and R 12b each independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1 -enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-ynyl yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl , oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN;methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl, hex-1-en-1-yl, hept-6-en-1 , hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, oct-4-yn-yl, oct-3-yn-yl , oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, and pyrazinyl are each optionally substituted with at least one substituent R; 11e replace; R 11e is, independently at each occurrence, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, vinyl, propenyl, allyl, but-3-en-1-yl, but-2-en-1-yl, but-1-en-1-yl, pent-4-en-1-yl, pent-3-en-1-yl, pent-2-en-1-yl, pent-1-en-1-yl, hex-5-en-1-yl, hex-4-en-1-yl, hex-3-en-1-yl, hex-2-en-1-yl. 1-enyl, hex-1-en-1-yl, hept-6-en-yl, hept-5-en-yl, hept-4-en-yl, hept-3-en-yl, hept-2-en-yl, hept-1-en-yl, oct-7-en-yl, oct-6-en-yl, oct-5-en-yl, oct-4-en-yl, oct-3-en-yl, oct-2-en-yl, oct-1-en-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1- yn-1-yl, pent-4-yn-1-yl, pent-3-yn-1-yl, pent-2-yn-1-yl, pent-1-yn-1-yl, hex-5-yn-1-yl, hex-4-yn-1-yl, hex-3-yn-1-yl, hex-2-yn-1-yl, hex-1-yn-1-yl, hept-6-yn-yl, hept-5-yn-yl, hept-4-yn-yl, hept-3-yn-yl, hept-2-yn-yl, hept-1-yn-yl, oct-7-yn-yl, oct-6-yn-yl, oct-5-yn-yl, yl, oct-4-yn-yl, oct-3-yn-yl, oct-2-yn-yl, oct-1-yn-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, -OR 11g or -CN; R 11g independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl; Preferably, R 11a , R 11b , R 12a and R 12b each independently selected from H, -CH3, -CF3, -CH2CH3, -CH2CF3, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyrrolidinyl, tetrahydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, benzyl, vinyl, propenyl, allyl, but-3-en-1-yl, ethynyl, prop-2-yn-1-yl, prop-1-yn-1-yl, but-3-yn-1-yl, but-2-yn-1-yl, but-1-yn-1-yl, 18. A compound as claimed in any one of the preceding claims, wherein (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R 12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6- or 8-membered unsaturated or saturated ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 11f replace; R 11f is independently at each occurrence hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl, 5- to 12-membered heteroaryl, oxo (=O), -OR 11g , thio (=S), -SR 11g 、-CN、-SO2R 11g 、-SO2NR 11g R 11h 、-COR 11g 、-CO2R 11h 、-CONR 11g R 11h 、-NR 11g R 11h 、-NR 11g COR 11h 、-NR 11g CO2R 11h or -NR 11g S02R 11h ; R 11g and R 11h are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C 1-8 Alkoxy-C 1-8 Alkyl-, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl; R 11i is independently at each occurrence -F, -Cl, -Br, -I, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 haloalkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C8 halocycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl or 5- to 12-membered heteroaryl; Preferably, (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R 12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the carbon atoms to which they are attached, form a 3-, 4-, 5-, 6- or 8-membered unsaturated or saturated ring; More preferably, (R 11a and R 11b )、(R 12a and R 12b )、(R 11a and R 12a )、(R 11a and R 12b )、(R 11b and R 12a ) or (R 11b and R 12b ) together with the carbon atoms to which they are attached form a 3-, 4-, 5-, 6-, or 8-membered saturated ring.

19. A compound as claimed in any one of the preceding claims, wherein R 13 , R 14a and R 14b R is each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or 3-8 membered heterocyclyl; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or 3-8 membered heterocyclyl is optionally substituted by at least one substituent R 13a replace; R 13a is independently at each occurrence halogen, -OH, -CN, oxo, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C 1-8 Haloalkyl, -C 1-8 Alkoxy, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 halocycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; Preferably, R 13 , R 14a and R 14b Each is independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or a 3- to 8-membered heterocyclyl; More preferably, R 13 is hydrogen, methyl, ethyl, propyl or butyl; R 14a and R 14b Each is independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or a 3- to 8-membered heterocyclyl; Even more preferably, R 13 is hydrogen; R 14a and R 14b Each is independently selected from hydrogen, methyl, ethyl, propyl, butyl, cyclopropyl, cyclobutyl, and cyclopentyl.

20. A compound as claimed in any one of the preceding claims, wherein R 1 Selected from 21. A compound as claimed in any one of the preceding claims, wherein R 2 independently selected from H, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -CN, -COR 2a 、-CO2R 2a 、-CONR 2a R 2b 、-NR 2a R 2b 、-NR 2a COR 2b , methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl and imidazopyridinyl is optionally substituted with at least one substituent R 2c replace; R 2a and R 2b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, is optionally substituted with at least one substituent R 2d replace; or R 2a and R 2b Together with the carbon atoms to which they are attached, they form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring containing 0, 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2d replace; R 2c and R 2d is independently at each occurrence hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, oxo (=O), -OR 2e 、-SR 2e 、-CN、-COR 2e 、-CO2R 2e 、-CONR 2e R 2f 、-NR 2e R 2f 、-NR 2e COR 2f or -NR 2e CO2R 2f ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, each of which is optionally substituted with at least one substituent R 2g replace; R 2e and R 2f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 2h replace; R 2g and R 2h is independently at each occurrence -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 1-8 Halogenated alkyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -C3-C8 halocycloalkyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

22. A compound as claimed in any one of the preceding claims, wherein R 2 independently selected from H, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -CN, -COR 2a 、-CO2R 2a or-CONR 2a R 2b , methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, each of which is optionally substituted with at least one substituent R 2c replace; R 2a and R 2b each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl; methyl, Each of ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, aziridinyl, azetidinyl, pyrrolidinyl, dihydropyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, oxazolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, is optionally substituted with at least one substituent R 2d replace; or R 2a and R 2b Together with the carbon atoms to which they are attached, they form a 3-, 4-, 5- or 6-membered unsaturated or saturated ring containing 0 or 1 heteroatom independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 2d replace; R 2c and R 2d is independently at each occurrence hydrogen (H or D), -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -OR 2e , -CN or -NR 2e R 2f methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, each of which is optionally substituted with at least one substituent R 2g replace; R 2e and R 2f R is each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or phenyl is optionally substituted with at least one substituent R 2h replace; R 2g and R 2h is independently at each occurrence -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; Preferably, R 2 yes -CH3、 23. A compound as claimed in any one of the preceding claims, wherein R 3 are independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl is optionally replaced by at least one selected from -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, -C6-C 12 aryl or 5- to 12-membered heteroaryl substituents; Preferably, R 3 are independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, or -CN; More preferably, R 3 Independently selected from hydrogen, -F, -Cl, -Br, -I.

24. A compound as claimed in any one of the preceding claims, wherein R 4 It is an oxo group (=O).

25. A compound as claimed in any one of the preceding claims, wherein R 3 and R 4 Together with the carbon atoms to which they are attached, they form a 5- to 6-membered aromatic ring, the ring containing 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 3a replace; R 3a are independently selected from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CN, wherein each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl is optionally replaced by at least one selected from -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclic group, -C6-C 12 The substituents are substituted by aryl or 5- to 12-membered heteroaryl.

26. A compound as claimed in any one of the preceding claims, wherein R 5 is phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -COR 5a 、-CO2R 5a or-CONR 5a R 5b , wherein each of phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5c replace; R 5a and R 5b Each is independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, oxadiazolyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, oxadiazolyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5d replace; or R 5a and R 5b Together with the nitrogen atom to which they are attached, they form a 3-, 4-, 5-, 6-, 7- or 8-membered unsaturated or saturated ring containing 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent R 5d replace; R 5c and R 5d is independently selected at each occurrence from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, oxo (=O), -OR 5e 、-SR 5e 、-CN、-COR 5e 、-CO2R 5e 、-CONR 5e R 5f 、-NR 5e R 5f 、-NR 5e COR 5f or -NR 5e CO2R 5f ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl each optionally substituted with at least one substituent R 5g replace; R 5e and R 5f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5h replace; R 5g and R 5h are each independently selected from halogen, -OH, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

27. A compound as claimed in any one of the preceding claims, wherein R 5 is pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl, wherein each of the pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl and imidazopyridinyl groups is optionally substituted with at least one substituent R 5c replace; R 5c is independently selected at each occurrence from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl; Preferably, R 5 is benzoxazolyl; More preferably, R 5 yes 28. A compound as claimed in any one of the preceding claims, wherein R 5 Yes-COR 5a 、-CO2R 5a or-CONR 5a R 5b ; Where R 5a and R 5b each independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, oxadiazolyl, triazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; Each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5d replace; R 5d is independently selected at each occurrence from hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl, imidazopyridinyl, -OR 5e or -CN; each of methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5g replace; R 5e is selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl; ... Each of phenyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, imidazopyridazinyl or imidazopyridinyl is optionally substituted with at least one substituent R 5h replace; R 5g and R 5h each independently selected from halogen, -OH, -CN, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, or 5- to 12-membered heteroaryl; Preferably, R 5 yes -COCH3 or -COCF3.

29. A compound as claimed in any one of the preceding claims, wherein R 6 is H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN, -OR 6a 、-NR 6a R 6b 、-COR 6a 、-CO2R 6a 、-CONR 6a R 6b 、-COR 6a or -NR 6a COR 6b , methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl is optionally substituted with at least one substituent R 6c replace; R 6a and R 6b are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 6d replace; R 6c is independently at each occurrence hydrogen, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, oxo (=O), -OR 6e 、-SR 6e 、-CN、-COR 6e 、-CO2R 6e 、-CONR 6e R 6f 、-NR 6e R 6f 、-NR 6e COR 6f or -NR 6e CO2R 6f ; methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, 5- to 12-membered heteroaryl, each of which is optionally substituted with at least one substituent R 6g replace; R 6e and R 6f are each independently selected from hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; R 6d and R 6g each independently selected from -F, -Cl, -Br, -I, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl.

30. A compound as claimed in any one of the preceding claims, wherein R 6 is H, -F, -Cl, -Br, -I, methyl, -CF3, ethyl, -CH2CF3, -CF2CH3, propyl, butyl, pentyl, hexyl, heptyl, octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, furanyl, thienyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, -CN, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, Preferably, Part is 31. A compound as claimed in any one of the preceding claims, wherein R 9 and R 10 Each is independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl or 5- to 12-membered heteroaryl, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Each of alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, or 5- to 12-membered heteroaryl is optionally substituted with at least one substituent R 9a replace; R 9a is independently at each occurrence halogen, -OH, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, C 1-8 Alkoxy-C 1-8 Alkyl-, -C 2-8 Alkenyl, -C 2-8 Alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; Preferably, R 9 and R 10 Each is independently selected from H, -F, -Cl, -Br, -I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl or 5- to 12-membered heteroaryl; More preferably, R 9 and R 10 Each is independently selected from H, methyl, ethyl, propyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl; More preferably, R 9 and R 10 Each is independently selected from H and cyclopropyl.

32. A compound as claimed in any one of the preceding claims, wherein the compound is selected from 33. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 32 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof, and a pharmaceutically acceptable excipient.

34. A method of reducing IL-17 activity by inhibition comprising administering to a subject a compound as described in any one of claims 1 to 32 or a pharmaceutically acceptable salt thereof, including a compound of formula (I) or a specific compound exemplified herein.

35. The method of claim 34, wherein the disease is selected from cancer.

36. Use of a compound as claimed in any one of claims 1 to 32 or a pharmaceutically acceptable salt, stereoisomer, tautomer or prodrug thereof in the preparation of a medicament for treating a disease that can be affected by IL-17.

37. The use of claim 36, wherein the disease is an autoimmune disease or an inflammatory disease.

38. The use according to claim 37, wherein the disease is chronic inflammation, psoriasis, spondyloarthritis, rheumatoid arthritis or multiple sclerosis.

Citation Information

Patent Citations

  • Compounds for modulating il-17

    WO2014066726A2

  • Spirocyclic indolines as il-17 modulators

    WO2018229079A1

  • Fused imidazole derivatives as il-17 modulators

    WO2019138017A1

  • Immunomodulator

    WO2019223718A1

  • Spirocyclic indane analogues as il-17 modulators

    WO2020011731A1

Cited By

  • Il-17a inhibitors

    WO2026193252A1